candesartan profile

Candesartan is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and heart failure. It works by blocking the effects of angiotensin II, a hormone that causes blood vessels to narrow. This helps to lower blood pressure and reduce the strain on the heart. Candesartan is a synthetic compound, developed by Takeda Pharmaceuticals, and was first approved for use in the United States in 1998. It is available in both generic and brand-name forms. Candesartan has been shown to be effective in lowering blood pressure and reducing the risk of cardiovascular events, such as heart attacks and strokes. It is often used in combination with other medications, such as diuretics and beta-blockers. The compound is being studied in clinical trials for its potential benefits in treating other conditions, such as diabetic nephropathy and preeclampsia. '

candesartan: a nonpeptide angiotensin II receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	2541
CHEMBL ID	1016
CHEBI ID	3347
SCHEMBL ID	3938
MeSH ID	M0217705

Synonym
BIDD:GT0350
CHEMBL1016 ,
nsc-759858
AB01275447-01
gtpl587
tcv-116 (prodrug)
2-ethoxy-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4ethyl]}-1h-benzimidazole-7-carboxylic acid
CHEBI:3347 ,
2-ethoxy-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid
cv-11974
2-ethoxy-1-({2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1h-benzimidazole-7-carboxylic acid
2-ethoxy-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-(ethyloxy)-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid
2-ethoxy-7-carboxy-1-(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole
cv 11974
c24h20n6o3
1h-benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
candesartan
139481-59-7
C07468
candesartan (usan/inn)
D00522
NCGC00167474-01
2-ethoxy-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1h-benzimidazole-7-carboxylic acid
HMS2089M22
2-ethoxy-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid(cv-11974)
bdbm50240609
2-ethoxy-3-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid
L000156
2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
A807545
2-ethoxy-3-[[4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-4-benzimidazolecarboxylic acid
A808309
NCGC00167474-02
unii-s8q36md2xx
ec 604-138-8
hsdb 7520
s8q36md2xx ,
candesartan [usan:inn:ban]
nsc 759858
2-ethoxy-1-((2-(1h-tetrazole-5-yl)biphenyl-4-yl)methyl)-1h-benzamidazole-7-carboxylic acid.
cas-139481-59-7
dtxcid202725
dtxsid0022725 ,
tox21_112478
nsc759858
BCP9000479
pharmakon1600-01502288
smr003500711
1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylic acid
MLS004774041
CANDESARTAN - ATACAND
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl] methyl]-3h-benzoimidazole-4-carboxylic acid
BCPP000302
smr002203608
MLS003915631
FT-0602912
AB07470
candesartan [vandf]
candesartan [who-dd]
candemore
candesartan [usan]
candesartan [inn]
candesartan [mi]
candesartan cilexetil impurity g [ep impurity]
candesartan [hsdb]
AM84369
S1578
AKOS015888154
gtpl6907
[3h]candesartan
CCG-213059
HY-B0205
SCHEMBL3938
NCGC00167474-04
tox21_112478_1
KS-5003 ,
1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylic acid
AKOS025117340
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzimidazole-4-carboxylic acid
2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]-benzimidazole-7-carboxylic acid
2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid
HTQMVQVXFRQIKW-UHFFFAOYSA-N
2-ethoxy-1-[[2'-(1 h-tetrazol-5-yl)biphenyl-4-yl]methyl]-benzimidazole-7-carboxylic acid
2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid
1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylic acid
AB01275447_02
AB01275447_03
2-ethoxy-1-({4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1h-1,3-benzodiazole-7-carboxylic acid
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid
mfcd00864463
SR-05000001447-5
sr-05000001447
HMS3651C13
SR-05000001447-1
SR-05000001447-2
J-007281
HMS3715F13
NCGC00167474-06
2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid (candesartan)
SW199612-2
2-ethoxy-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid
DB13919
Q415970
candesartan (atacand)
BCP01137
2-ethoxy-1-{[2'-(2h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-1,3-benzodiazole-7-carboxylic acid
STR09609
CCG-269122
2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid.
C-266
1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylicacid
nsc755311
candesartan 100 microg/ml in acetonitrile:methanol
nsc-755311
celexetil
candesartan- bio-x
BC164271
2-ethoxy-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-1,3-benzodiazole-7-carboxylic acid
EN300-6491073
Z1741968269
1-[(2 inverted exclamation mark -(5-tetrazolyl)-4-biphenylyl)methyl]-2-ethoxybenzimidazole-7-carboxylic acid
SY065768
2-ethoxy-1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1h-benzimidazole-7-carboxylic acid
c09ca06
2-ethoxy-1-((2'-(1h-tetrazol-5-yl)biphenyl-4ethyl))-1h-benzimidazole-7-carboxylic acid
candesartanum
2-ethoxy-3-((4-(2-(2h-tetrazol-5-yl)phenyl)phenyl)methyl)-3h-benzoimidazole-4-carboxylic acid

Excerpt	Reference	Relevance
"Candesartan is an angiotensin II-receptor blocker and has proved neuroprotective properties."	( Candesartan protects against d-galactose induced - Neurotoxicity and memory deficit via modulation of autophagy and oxidative stress. Abo-Saif, MA; Khedr, NF; Werida, RH, 2022)	2.89
"Candesartan is an angiotensin II (Ang II) receptor antagonist with promising diverse health benefits."	( Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-κB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1-7 Signals. Ahmed, MA; Ali, FEM; Gad-Elrab, WM; Hassanein, EHM; Kamel, EO; Mohammedsaleh, ZM, 2023)	3.07
"Candesartan is an angiotensin II receptor antagonist widely used as a blood pressure-lowering drug; however, the inhibitory potential of candesartan on the NLRP3 inflammasome has not yet been investigated."	( Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity. Cheng, SM; Chernikov, OV; Chiu, HW; Ho, CL; Hsiao, YY; Hsu, HT; Hua, KF; Li, LH; Lin, WY; Peng, YJ; Wong, WT; Yang, SP, 2022)	1.69
"Candesartan (Cand) is an angiotensin receptor antagonist widely used for hypertension treatment."	( Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy. Calleros, L; De Giusti, V; Ferrer, EG; Griera, M; Islas, MS; Jaquenod de Giusti, C; Martinez, VR; Martins Lima, A; Portiansky, EL; Rodriguez Puyol, M; Stergiopulos, N; Velez Rueda, JO; Williams, PAM, 2023)	1.9
"Candesartan is a nonpeptide angiotensin II receptor blocker that selectively binds to angiotensin II receptor subtype 1. "	( Candesartan exhibits low intrinsic permeation capacity and affects buccal tissue viability and integrity: An ex vivo study in porcine buccal mucosa. Garcia-Tarazona, YM; Gordillo, JFI; Lafaurie, GI; Morantes, SJ; Ramos, FA; Sepúlveda, P, 2023)	3.8
"Candesartan (Cands) is an angiotensin receptor blocker that has the potential to prevent cognitive deficits."	( Effect of safranal or candesartan on 3-nitropropionicacid-induced biochemical, behavioral and histological alterations in a rat model of Huntington's disease. Abd El-Salam, DM; Hussein, RM; Rizk, SM; Shehata, NI, 2023)	1.95
"Candesartan is an ARB that has also been known for its anticancer effects but the exact molecular mechanism is remaining elusive."	( Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux. Park, SY; Rasheduzzaman, M, 2018)	1.52
"Candesartan is a poorly water-soluble drug having an anti-hypertensive activity."	( Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug. Fatima, Z; Kaur, CD; Nashik, SS; Rizvi, DA; Srivastava, D; Tulsankar, SL, 2019)	1.24
"Candesartan (CDS) is an AT1 receptor antagonist with potential neuroprotective properties."	( Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. Berk, M; Budni, J; Carvalho, AF; Cavalcante, LM; de Lucena, DF; de Sousa, FC; de Souza Gomes, JA; de Souza, GC; Macêdo, D; Quevedo, J, 2015)	1.44
"Candesartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker (ARB). "	( A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. , 2011)	2.08
"Candesartan is an angiotensin II type 1 receptor blocker (ARB) that has been to shown to limit ischemic stroke and improve stroke outcome. "	( AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. Alhusban, A; Ergul, A; Fagan, SC; Kozak, A, 2013)	1.83
"Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor. "	( [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004)	2.68
"Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor. "	( Candesartan for the treatment of hypertension and heart failure. Ostergren, J, 2004)	3.21
"Thus candesartan is considered to be a unique, attractive choice of prophylactic agent for migraine complicated by hypertension."	( Efficacy of candesartan in the treatment of migraine in hypertensive patients. Owada, K, 2004)	1.16
"Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the gastrointestinal tract, with insurmountable receptor binding abilities. "	( Candesartan for the management of heart failure: more than an alternative. McKelvie, RS, 2006)	3.22
"Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1. "	( Candesartan in heart failure. Chonlahan, JS; Germany, RE; Ripley, TL, 2006)	3.22
"Candesartan is an insurmountable blocker with a slow dissociation from the AT1 receptor, and it has been shown to effectively reduce BP in humans and in a variety of genetic and experimental models of hypertension."	( Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. Morsing, P, 1999)	2.47
"Candesartan is an angiotensin II subtype 1 (AT1) receptor antagonist that is administered orally as candesartan cilexetil which is converted in the active compound."	( Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Buter, H; de Jong, PE; de Zeeuw, D; Navis, GY; Woittiez, AJ, 1999)	1.29
"Candesartan (Atacand) is a novel antagonist of angiotensin II AT1 receptors. "	( [Pharma-clinics. The drug of the month. Candesartan (Atacand)]. Kulbertus, H, 1999)	2.01
"Candesartan cilexetil is an angiotensin II receptor antagonist, and candesartan, its active metabolite, is metabolized by CYP2C9. "	( CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Azuma, J; Fukuda, T; Funae, Y; Hanatani, T; Hiroi, T; Ikeda, M; Imaoka, S, 2001)	1.99

Excerpt	Reference	Relevance
"Candesartan has a preventive value against atherosclerotic plaque rupture in hypercholesterolemic rabbits, likely through its reduction of MMP-9 expression, inhibition of macrophage accumulation and increase of collagen content within the plaques."	( [Prevention of rupture of atherosclerotic plaque by Candesartan in rabbit model]. Li, SA; Meng, ZM; Qian, HD; Shen, L; Wu, AS; Yin, HC; Yu, T; Zhou, XF; Zhu, WL, 2010)	2.05
"Candesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%."	( Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Granger, CB; Held, P; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Yusuf, S, 2003)	2.15
"Candesartan has a favorable effect on large artery function in patients with chronic heart failure."	( Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. Arnold, JM; Desai, SS; Dunlap, ME; Granger, CB; Marchiori, G; Mitchell, GF; O'Brien, TX; Pfeffer, MA; Warner, E, 2006)	2.06
"Candesartan has the most positive effects on skin cells."	( Side Effects of Frequently Used Antihypertensive Drugs on Wound Healing in vitro. Bachmann, HS; Besser, M; Severing, AL; Stuermer, EK; Terberger, N, 2019)	1.24
"Candesartan has been reported to have a protective effect on cerebral ischemia in vivo and in human ischemic stroke. "	( Candesartan improves ischemia-induced impairment of the blood-brain barrier in vitro. Deli, MA; Hayashi, K; Hiu, T; Matsuo, T; Morofuji, Y; Nagata, I; Nakagawa, S; Niwa, M; So, G; Suyama, K; Tanaka, K, 2015)	3.3
"Candesartan has been reported to reduce cardiovascular events when therapy was started 6 months after PCI with bare-metal stents in patients who survived restenosis. "	( Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. Hokimoto, S; Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Tsujita, K; Yamamoto, N, 2016)	2.28
"Candesartan has a preventive value against atherosclerotic plaque rupture in hypercholesterolemic rabbits, likely through its reduction of MMP-9 expression, inhibition of macrophage accumulation and increase of collagen content within the plaques."	( [Prevention of rupture of atherosclerotic plaque by Candesartan in rabbit model]. Li, SA; Meng, ZM; Qian, HD; Shen, L; Wu, AS; Yin, HC; Yu, T; Zhou, XF; Zhu, WL, 2010)	2.05
"Candesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%."	( Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Granger, CB; Held, P; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Yusuf, S, 2003)	2.15
"Candesartan has a favorable effect on large artery function in patients with chronic heart failure."	( Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. Arnold, JM; Desai, SS; Dunlap, ME; Granger, CB; Marchiori, G; Mitchell, GF; O'Brien, TX; Pfeffer, MA; Warner, E, 2006)	2.06
"Candesartan has no additional effect on the rates of postoperative AF when added to ACEI."	( Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation. Dede, O; Duver, H; Ibrisim, E; Kapan, S; Ozaydin, M; Peker, O; Turker, Y; Varol, E, 2008)	1.07
"Candesartan has been reported to produce nitric oxide (NO) and to decrease oxidative stress in animal studies. "	( Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Fujiwara, H; Hiei, K; Kawasaki, H; Minatoguchi, S; Mizukusa, T; Ono, H; Takahashi, H; Tsukamoto, T; Uno, T; Watanabe, K; Yamada, Y, 2008)	3.23
"Candesartan has favorable effects on renal function demonstrated in both humans and animals, and has also been shown to protect the kidney in several models of renal injury."	( Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. Morsing, P, 1999)	2.47

Excerpt	Reference	Relevance
"Candesartan had a lower Kaplan-Meier rate of NOD than amlodipine (8.3 vs."	( Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018)	1.2
"Candesartan promotes angiogenesis and activates MMPs."	( Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke. Fagan, SC; Fouda, AY; Ishrat, T; Patel, A; Pillai, B; Soliman, S, 2015)	1.41
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."	( Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)	1.34
"Candesartan induced an increase in plasma renin activity and plasma angiotensin II associated with a reduction in arterial pressure without affecting heart rate."	( Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure. Hikosaka, M; Iwasaka, T; Iwasaki, M; Kawamura, A; Mimura, J; Motohiro, M; Sugiura, T; Yuasa, F; Yuyama, R, 2002)	2.48
"Candesartan promotes a complementary antiproteinuric and a small antihypertensive effect after a treatment period of 8 weeks in patients with chronic glomerulonephritis when given in conjunction with an ACEI. "	( Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. Bader, BD; Berger, ED; Ebert, C; Erley, CM; Risler, T, 2002)	1.76

Excerpt	Reference	Relevance
"Candesartan treatment alleviated matrisome protein accumulation and normalized the vascular distensibility and cerebral blood flow."	( Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model. Ando, S; Fujita, N; Fukunaga, M; Hasegawa, M; Hatano, Y; Hirokawa, S; Igarashi, H; Ihara, M; Kakita, A; Kametani, F; Kanazawa, M; Kato, T; Kawashima, Y; Kawata, H; Koyama, A; Manabe, RI; Matsumoto, M; Murayama, S; Nishizawa, M; Nozaki, H; Onodera, O; Saito, R; Saito, S; Sato, T; Sekine, Y; Sugai, A; Sugie, A; Toyoshima, Y; Tsuji, S; Uemura, M, 2021)	2.79
"Candesartan treatment (10 or 30 mg/kg; orally) was initiated one day post CLI and thereafter once daily for up to 14 days."	( Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway. Abdelaziz, RR; Elshaer, SL; Khaled, S; Suddek, GM, 2023)	3.07
"Candesartan treatment reduced the expression of M1 markers, and increased M2 markers."	( Candesartan modulates microglia activation and polarization via NF-κB signaling pathway. Gong, W; Li, W; Liu, Z; Lu, X; Qie, S; Ran, Y; Su, W; Xi, J, )	2.3
"Candesartan treatment also inhibits the expression of anti-apoptotic protein c-FLIP."	( Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux. Park, SY; Rasheduzzaman, M, 2018)	1.52
"Candesartan treatment improved neurobehavioral and motor function, and decreased infarct size and Hb."	( Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia. Eldahshan, W; Ergul, A; Fagan, SC; Ishrat, T; Pillai, B; Soliman, S, 2018)	1.45
"Candesartan treatment also increased the amount of fecal short-chain fatty acids (SCFAs) including acetic acid, propionic acid, and butyric acid in SHRs."	( Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. Chen, Y; Cui, J; Ding, L; Du, X; Tang, X; Wang, P; Wang, W; Wu, D; Yin, J; Zhang, T, 2019)	2.68
"Candesartan and tempol treatments also significantly improved conducted vasodilatation."	( Spreading vasodilatation in the murine microcirculation: attenuation by oxidative stress-induced change in electromechanical coupling. Chaston, DJ; Edwards, FR; Hill, CE; Howitt, L; Matthaei, KI; Sandow, SL, 2013)	1.11
"All candesartan-treated rabbits showed significantly attenuated atherosclerosis lesions with reduced accumulation of monocytes and had significantly reduced VCAM-1 expression and NF-κβ activity."	( Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. Abdulzahra, MS; Al-Amran, FG; Hadi, NR; Majeed, ML; Mohammad, BI; Yousif, MG; Yousif, NG, 2013)	1.09
"Candesartan-treated animals showed a significant reduction in the infarct size [t (13) = -5.5, P = 0.0001] accompanied by functional recovery in Bederson [F (1, 13) = 7.9, P = 0.015], beam walk [F (1, 13) = 6.7, P = 0.023], grip strength [F (1, 13) = 15.2, P = 0.0031], and rotarod performance [F (1, 14) = 29.8, P < 0.0001]."	( Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Soliman, S, 2015)	1.56
"Candesartan treatment restored the functionality of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis by inhibiting the proinflammatory-redox AT1-mediated mechanism."	( MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality. da Silva, CHTP; de Oliveira, AM; do Prado, AF; Gerlach, RF; Gomes, MS; Pernomian, L, 2015)	1.37
"Candesartan treatment was associated with increased iNOS expression (p = .033)."	( Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus. Bratlie, SO; Casselbrant, A; Edebo, A; Fändriks, L, 2017)	1.18
"Candesartan pretreatment reduced the LPS-induced release of TNF-alpha, IL-1beta, and IL-6 into the circulation."	( Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen. Baliova, M; Benicky, J; Larrayoz, IM; Nishioku, T; Pavel, J; Saavedra, JM; Sánchez-Lemus, E; Zhou, J, 2009)	1.07
"Candesartan treatment resulted in increased vascular density in the striatum at 7 days (P=0.037)."	( Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009)	2.52
"Candesartan treatment significantly elevated (p < 0.01) the total volume of the MD, whereas the total number of MD cells was increased [from 14.2 (0.11) to 19.5 (0.11)]."	( The effect of angiotensin II on the number of macula densa cells through the AT1 receptor. Nyengaard, JR; Razga, Z, 2009)	1.07
"Candesartan treatment induced a significant improvement in Forns Index, APRI and FibroIndex during treatment in comparison with the control group."	( Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Koda, M; Mitsuta, A; Murawaki, Y; Shimizu, T; Ueki, M; Yamamoto, T, )	1.1
"Candesartan treatment significantly reversed the increases in both AQP2 and p-AQP2 expression and targeting."	( Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade. Frøkiaer, J; Jonassen, T; Kim, SW; Knepper, MA; Kwon, TH; Lütken, SC; Marples, D; Nielsen, S, 2009)	1.07
"Candesartan-pretreated SHHF (5 mg/kg/day candesartan; weeks 4-8) received during adulthood (20-28 weeks of age) either candesartan at a dose of 1.5 or 5 mg/kg/day or vehicle."	( Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment. Baumann, M; Heemann, U; Lutz, J; Roos, M; Sollinger, D, 2010)	1.08
"Candesartan treatment increased AT1a receptor mRNA expression in the heart but not in the aorta of SHR."	( The mechanism of distinct diurnal variations of renin-angiotensin system in aorta and heart of spontaneously hypertensive rats. Masuyama, T; Matsumoto, M; Naito, Y; Ohyanagi, M; Okuda, S; Sakoda, T; Tsujino, T, 2009)	1.07
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."	( Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)	1.34
"Candesartan treatment significantly increased the level of plasma Ile(5)-Ang II (24.0+/-7.6 versus 156.9+/-24.6 fmol/mL; P<0.01); in contrast, there was a markedly lower intrarenal Ile(5)-Ang II content (357.9+/-76.6 versus 21.1+/-2.8 fmol/g; P<0.01)."	( Angiotensin II type 1 receptor-mediated augmentation of urinary excretion of endogenous angiotensin II in Val5-angiotensin II-infused rats. Navar, LG; Seth, DM; Shao, W, 2010)	1.08
"The candesartan-treated rats were healthy and had weight gain similar to that of the control rats, although a significant reduction in blood pressure was observed. "	( Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys. Akanae, W; Nonomura, N; Okuyama, A; Tsujihata, M; Yoshioka, I, 2011)	1.2
"Candesartan cilexetil treatments significantly reduced blood pressure (BP) in rats administered the high dose and moderately in rats receiving the low dose."	( Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011)	1.09
"Candesartan treatment significantly reduced the morning and office BPs compared with other ARBs in Japanese patients with morning hypertension."	( Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Hasegawa, H; Kameda, Y; Kobayashi, Y; Komuro, I; Kubota, A; Takano, H, 2012)	1.33
"In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced."	( Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Briones, AM; Burger, D; Burns, KD; Callera, GE; Corrêa, JW; Gagnon, AM; Gomez-Sanchez, CE; Gomez-Sanchez, EP; He, Y; Nguyen Dinh Cat, A; Ooi, TC; Ruzicka, M; Sorisky, A; Touyz, RM; Yogi, A, 2012)	0.89
"Candesartan treatment acutely recruited microvasculature in both skeletal and cardiac muscle by significantly increasing MBV (P < 0.03 and P = 0.02, respectively) and MBF (P < 0.03 for both) without altering microvascular flow velocity. "	( Candesartan acutely recruits skeletal and cardiac muscle microvasculature in healthy humans. Chai, W; Fowler, DE; Jahn, LA; Liu, J; Liu, Z; Sauder, MA, 2012)	3.26
"The candesartan treatment was stopped and oral corticosteroid therapy (50 mg/day) initiated."	( [Centrilobular nodules with ground-glass opacities in the lungs]. Ella Ondo, T; Iba Ba, J; Mounguengui, D, )	0.61
"Candesartan treatment reduced the lesion volume after CCI injury by approximately 50%, decreased the number of dying neurons, lessened the number of activated microglial cells, protected cerebral blood flow (CBF), and reduced the expression of the cytokine TGFβ1 while increasing expression of TGFβ3."	( Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Logan, TT; Saavedra, JM; Sánchez-Lemus, E; Symes, AJ; Villapol, S; Yaszemski, AK, 2012)	2.54
"Candesartan treatment for 4 weeks significantly reduced these parameters."	( Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. Chen, X; Endo, S; Guo, Q; Hu, C; Ito, S; Jiang, Y; Miyata, T; Mori, T; Nakayama, K; Nakayama, M; Ogawa, S; Ohsaki, Y; Yoneki, Y; Zhu, W, 2013)	1.11
"Candesartan treatment markedly reduced the mean arterial pressure of controls and glucose-intolerant rats."	( Renoprotective effects of chronic candesartan treatment in uninephrectomized rat. Mozaffari, MS; Patel, KB; Schaffer, SW, 2003)	1.32
"Candesartan-based treatment reduced non-fatal stroke by 27.8% (95% CI, 1.3 to 47.2, P = 0.04), and all stroke by 23.6% (95% CI, -0.7 to 42.1, P = 0.056)."	( The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Elmfeldt, D; Hansson, L; Hofman, A; Lithell, H; Olofsson, B; Skoog, I; Trenkwalder, P; Zanchetti, A, 2003)	1.04
"Candesartan treatment reduced (P < 0.05) media area in SHR without affecting vessel or lumen area."	( Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Cachofeiro, V; Cediel, E; de las Heras, N; González Pacheco, FR; Jiménez, J; Lahera, V; Oubina, MP; Sanz-Rosa, D; Vegazo, O, 2003)	1.04
"Candesartan treatment decreased cardiac PAI-1 expression only in the dark in WKY rats but throughout the day in SHR."	( Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats. Fujioka, Y; Iwasaki, T; Kawasaki, D; Masai, M; Morimoto, S; Naito, Y; Ohyanagi, M; Okumura, T; Sakoda, T; Tsujino, T, 2003)	1.04
"Candesartan treatment prevented the hypertension (87 +/- 3 mmHg) and led to increased plasma Ang II concentrations (441 +/- 27 fmol/ml), but prevented increases in kidney (120 +/- 15 fmol/g) and renal interstitial fluid (2.15 +/- 0.12 pmol/ml) Ang II concentrations."	( Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension. Navar, LG; Nishiyama, A; Seth, DM, 2003)	1.04
"Candesartan cilexetil treatment significantly reduced the fibrosis development. "	( Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Bayram, I; Ozbek, H; Tuncer, I; Ugras, S, 2003)	2.03
"Candesartan treatment reduced primary end point risk (5.9% vs 12.3% for control subjects; relative risk, 0.47; 95% CI, 0.24 to 0.93)."	( Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Kondo, J; Kono, T; Kosaka, T; Matsui, H; Morishima, I; Mukawa, H; Murohara, T; Numaguchi, Y; Okumura, K; Sone, T; Tsuboi, H; Uesugi, M; Yoshida, T, 2003)	1.29
"Candesartan treatment, however, attenuated the chronic tubulointerstitial injury in obstructed kidneys and was associated with significant preservation of kidney tissue mass."	( AT1A-mediated activation of kidney JNK1 and SMAD2 in obstructive uropathy: preservation of kidney tissue mass using candesartan. Padda, R; Sheikh-Hamad, D; Truong, LD; Tsao, CC; Wamsley-Davis, A; Zhang, P, 2004)	1.25
"Candesartan treatment resulted in a significant decrease of systolic and diastolic blood pressures, LV mass index (LVMI), homeostasis model assessment (HOMA) index, and plasma brain natriuretic peptide (BNP)."	( Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Anan, F; Hara, M; Ooie, T; Saikawa, T; Takahashi, N; Yoshimatsu, H, 2004)	2.49
"Candesartan treatment in macroalbuminuric patients significantly changed 15 of the 113 polypeptides in the diabetic renal damage pattern toward levels in normoalbuminuric patients."	( Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Christensen, PK; Hillmann, M; Kaiser, T; Mischak, H; Parving, HH; Rossing, K; Walden, M, 2005)	1.05
"Candesartan treatment was continued for 28 days."	( Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Aizawa, Y; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, S; Prakash, P; Soga, M; Tachikawa, H; Veeraveedu, P; Watanabe, K, 2006)	1.32
"Candesartan treatment completely suppressed the increases of p21, p27, p53 and Rb."	( Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. Izumi, T; Kosugi, R; Machida, Y; Shioi, T; Takahashi, K; Watanabe-Maeda, K; Yoshida, Y, 2006)	1.06
"Candesartan treatment increased Aogen, ACE and AT2 receptor in SHR, and increased ACE and decreased Aogen in WKY rats, without affecting the (pro)renin and AT1 receptors."	( AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Delgiacco, E; Dou, J; Ge, L; Imboden, H; Macova, M; Nishioku, T; Pavel, J; Saavedra, JM; Yu, ZX; Zhou, J, 2006)	1.06
"With candesartan-based treatment, compared with control, the relative risk of non-fatal stroke was 0.72 (P = 0.04) and of major cardiovascular events 0.89 (P = 0.19)."	( The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses. Trenkwalder, P, 2006)	0.79
"Candesartan treatment from the onset of obstruction attenuated the reduction in GFR (3.1 +/- 0.4 vs."	( Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction. Frische, S; Frøkiaer, J; Jensen, AM; Knepper, MA; Li, C; Nielsen, S; Nørregaard, R; Praetorius, HA, 2006)	1.06
"Candesartan-treated mice demonstrated significantly lower liver weights and reduced lipid droplets in hepatic cells compared with control mice."	( Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes. Itoh, T; Kanda, T; Kawaura, K; Kusaka, K; Morimoto, S; Moriya, J; Sumino, H; Takahashi, T; Yamakawa, J; Yu, F, )	0.85
"With candesartan pretreatment, LV fractional shortening and ejection fraction increased (P<0.05) by 37% and 28%, and LV chamber dilation was attenuated (P<0.05)."	( Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction. Castellano, L; Do, R; Gaballa, MA; Goldman, S; Juneman, E; Phan, H; Thai, H, 2006)	0.79
"In candesartan-treated piglets, the l-NAME-induced GFR reduction seen in normal and nonobstructed kidneys was absent in the partial obstructed kidneys."	( Glomerular and tubular function during AT1 receptor blockade in pigs with neonatal induced partial ureteropelvic obstruction. Djurhuus, JC; Eskild-Jensen, A; Ferreira, LS; Frøkiaer, J; Nielsen, S; Nyengaard, JR; Paulsen, LF; Rawashdeh, YF; Rungø, C; Thomsen, K, 2007)	0.85
"Candesartan treatment also notably decreased staining intensity of oxidative stress markers, as well as attenuating intra-islet fibrosis and improving blood supply in the islet."	( Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice. Du, H; Iwashita, N; Kawamori, R; Shao, JQ; Wang, J; Wang, YT; Wang, YY; Watada, H; Zhao, M, 2007)	1.06
"Candesartan treatment of DS rats with established diastolic heart failure reversed cardiac remodeling, improved cardiac relaxation abnormality, and prolonged survival, being accompanied by the attenuation of the increase in cardiac superoxide, reduced nicotinamide-adenine dinucleotide phosphate oxidase, and xanthine oxidoreductase activities."	( Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007)	1.29
"Candesartan treatment improved myocardial injury in obese mice with acute viral myocarditis and induced expression of cardiac adiponectin with the induction of C/EBPalpha as well as the reduction of cardiac NF-kappaB and TNF-alpha."	( Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Chen, R; Iwai, K; Kanda, T; Matsumoto, M; Morimoto, S; Nakahashi, T; Sumino, H; Takahashi, T; Yu, F, 2008)	3.23
"Candesartan treatment significantly improved RBF (+40% +/- 6% vs."	( Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction. Grimberg, E; Guron, G; Nitescu, N, 2008)	1.48
"In candesartan-treated DM rats, UT-A3 increased in IM tip (160 +/- 14%) and base (210 +/- 19%)."	( Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney. Blount, MA; Kent, KJ; Klein, JD; Price, SR; Sands, JM; Smith, TD, 2008)	2.3
"Candesartan treatment attenuated the sodium-retaining action of hyperinsulinaemia."	( Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. Higashiura, K; Miyazaki, Y; Shimamoto, K; Ura, N, 1999)	1.28
"Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR. "	( Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Ito, T; Nishimura, Y; Saavedra, JM, 2000)	1.75
"Candesartan treatment for 1 week reduced aortic and cardiac PAI-1 expression in spontaneously hypertensive rats by 94% and 72%, respectively (P<0.05), but did not affect vascular PAI-1 levels in Wistar-Kyoto rats."	( Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Bouchie, JL; Chen, HC; Clermont, AC; Feener, EP; Hampe, J; Izumo, S; Perez, AS, 2000)	1.03
"Candesartan-treated animals maintained mesenteric and jejunal mucosal perfusion during 40% hypovolemia compared to CTRL animals, while no differences were observed in the hepatic and renal circulation."	( Angiotensin II blockade in existing hypovolemia: effects of candesartan in the porcine splanchnic and renal circulation. Aneman, A; Ewert, S; Fändriks, L; Laesser, M; Pettersson, A, 2000)	1.27
"Candesartan treatment (n=8) also prevented increases in kidney (215+/-19 fmol/g), endosomal (96+/-29 fmol/mg protein), and intermicrovillar cleft Ang II levels (11+/-2 fmol/mg protein)."	( Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Benes, E; Hammond, TG; Imig, JD; Navar, LG; Orengo, S; Zhuo, JL, 2002)	1.04
"Candesartan treatment normalised the lower part of the autoregulatory curve in SHR, and markedly decreased cerebral ischaemia as a consequence of middle cerebral artery occlusion with reperfusion."	( Pre-treatment with candesartan protects from cerebral ischaemia. Ito, T; Nishimura, Y; Saavedra, J, 2001)	1.36
"Candesartan treatment ameliorated the glomerular morphological findings at six weeks after disease induction."	( Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. Gejyo, F; Ikezumi, Y; Ito, Y; Kawachi, H; Koike, H; Morioka, Y; Nakamura, T; Nakatsue, T; Natori, Y; Oyanagi, A; Shimizu, F, 2002)	1.04
"Treatment with candesartan and C21 was started on day 1, before VCR treatment, and continued until day 7."	( Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia. Bessaguet, F; Bouchenaki, H; Danigo, A; Demiot, C; Desmoulière, A; Duchesne, M; Magy, L; Richard, L; Sturtz, F, 2018)	0.82
"Treatment with candesartan had no influence on serum YKL-40 levels."	( Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Arnesen, H; Seljeflot, I; Smith, P; Svendsen, JH; Tveit, A, 2013)	0.73
"Treatment with candesartan completely abrogated the emergence of the enlarged cells but did not reverse the Ito, and IKur in normal-sized cells in DCM hearts."	( Effects of candesartan on electrical remodeling in the hearts of inherited dilated cardiomyopathy model mice. Daida, H; Inoue, H; Konishi, M; Kurebayashi, N; Morimoto, S; Murayama, T; Nakazato, Y; Odagiri, F; Sakurai, T; Shioya, T; Sugihara, M; Suzuki, T, 2014)	1.13
"Treatment with candesartan in the early phases of acute necrotizing pancreatitis effective on microcirculation of pancreatic tissue (Tab. "	( Candesartan mediates microcirculation in acute necrotizing pancreatitis. Bostanci, H; Dikmen, AU; Dikmen, K; Gulbahar, O; Poyraz, A; Sahin, TT; Tekin, E; Yuksel, O, 2015)	2.21
"Treatment with candesartan in the acute phase of stroke was not associated with clear long-term clinical benefits. "	( Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015)	1.16
"Treatment with candesartan did not influence the levels of hs-TnI."	( High-Sensitivity Troponin I and Rhythm Outcome after Electrical Cardioversion for Persistent Atrial Fibrillation. Arnesen, H; Horjen, AW; Norseth, J; Seljeflot, I; Smith, P; Tveit, A; Ulimoen, SR, 2016)	0.77
"Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy."	( Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2008)	1.1
"Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice."	( Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. Hashimoto, T; Hirawa, N; Imai, N; Ishigami, T; Kihara, M; Kitamura, H; Kiuchi, Y; Nomura, K; Tamura, K; Toya, Y; Umemura, S; Yasuzaki, H; Yoshida, S, 2009)	0.93
"Pretreatment with candesartan profoundly modifies the response to stress."	( Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Benicky, J; Murakami, Y; Pavel, J; Saavedra, JM; Sanchez-Lemus, E, 2008)	0.67
"Treatment with candesartan was associated with a shorter FPD in patients remaining in sinus rhythm for 6 months."	( Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation. Arnesen, H; Grundvold, I; Hegbom, F; Smith, P; Tveit, A, 2009)	0.71
"Treatment with candesartan did not reduce or prevent the development of excessive excretion of urinary albumin."	( Albuminuria in chronic heart failure: prevalence and prognostic importance. Gerstein, HC; Granger, CB; Jackson, CE; McMurray, JJ; Michelson, EL; Olofsson, B; Pfeffer, MA; Solomon, SD; Swedberg, K; Yusuf, S; Zetterstrand, S, 2009)	0.69
"When treated with candesartan, but not CCBs, CAVI significantly decreased from 8.7 to 7.7 by 11%."	( Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Mito, A; Sakoda, M, 2010)	0.96
"The treatment with candesartan significantly reduced CTGF expression and effectively suppressed the development of fibrotic deposition in diabetic animals."	( Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling. Aizawa, T; Fu, LT; Kaneko, S; Kato, T; Sagara, K; Sekiguchi, A; Takamura, M; Tsuneda, T; Yamashita, T, 2011)	0.69
"Treatment with candesartan improved lipid peroxidation and primary hemostasis."	( [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan]. Medvedev, IN; Simonenko, VB; Tolmachev, VV, 2011)	0.92
"Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury."	( Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. Fujita, T; Hirooka, K; Itano, T; Lei, B; Liu, Y; Nakamura, T; Nishiyama, A; Shiraga, F; Zhang, J, 2012)	0.7
"Treatment with Candesartan (2mg/kg per day) could effectively downregulate Smad3 and fibronectin accompanied by upregulating of Smad7."	( Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. Li, H; Liu, X; Wang, S; Yu, H; Zhao, G, 2012)	2.16
"Pretreatment with candesartan significantly inhibited Ang II- induced JAK/STAT3 phosphorylation."	( Effect of angiotensin II on proliferation and differentiation of mouse induced pluripotent stem cells into mesodermal progenitor cells. Goshima, H; Ishizuka, T; Ozawa, A; Watanabe, Y, 2012)	0.7
"Treatment with candesartan alone increased cortical BZ(1) binding, and decreased γ(2) subunit mRNA expression in the cingulate cortex."	( Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress. Honda, M; Saavedra, JM; Sánchez-Lemus, E, 2012)	0.99
"Pretreatment with candesartan for 10 days reduced significantly the ulcer index induced by indomethacin injection."	( Immunomodulatory effect of candesartan on indomethacin-induced gastric ulcer in rats. Awad, AS; El Morsy, EM; Kamel, R, 2012)	1
"Oral treatment with candesartan increased the nonlinearity and reduced the linearity in SHR."	( Potentiated sympathetic nervous and renin-angiotensin systems reduce nonlinear correlation between sympathetic activity and blood pressure in conscious spontaneously hypertensive rats. Imai, M; Kumagai, H; Matsuura, T; Onami, T; Osaka, M; Sakata, K; Saruta, T, 2002)	0.63
"Treatment with candesartan, but not FK506, prevented the upregulation of ACE and TGF-beta1 gene expression."	( AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Ichihara, S; Iwase, M; Izawa, H; Nagasaka, T; Nagata, K; Nakashima, N; Obata, K; Odashima, M; Somura, F; Yamada, Y; Yokota, M, 2002)	0.65
"Pretreatment with candesartan for 3 days or nicardipine for 28 days was ineffective."	( Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Bregonzio, C; Falcón-Neri, A; Ito, T; Saavedra, JM; Terrón, JA; Yamakawa, H, 2002)	0.64
"Treatment with candesartan, an angiotensin-II-receptor blocker (ARB), controlled both hypertension and proteinuria satisfactorily without worsening of his renal function."	( A case of nephrotic syndrome associated with renovascular hypertension successfully treated with candesartan. Chinda, J; Hasebe, N; Hirayama, T; Imamoto, C; Kikuchi, K; Okada, M; Takahashi, F; Takeuchi, T, 2003)	0.88
"Treatment with candesartan enhanced (P < 0.05) ACh relaxations in SHR and reduced (P < 0.05) ACh + l-NAME contractions in both strains."	( Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Cachofeiro, V; Cediel, E; de las Heras, N; González Pacheco, FR; Jiménez, J; Lahera, V; Oubina, MP; Sanz-Rosa, D; Vegazo, O, 2003)	0.66
"pretreatment with candesartan, 0.1 and 0.3 mg/kg, dose-dependently decreased MAP before, during and after ischaemic injury but did not improve recovery from brain ischaemia."	( Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. Blume, A; Culman, J; Gohlke, P; Groth, W; Unger, T, 2003)	0.94
"Pre-treatment with candesartan resulted in higher survival rate (83%, 10 out of 12 animals) compared with 50% (6 of 12) in control animals and 27% (3 of 11) in animals treated during endotoxinemia. "	( The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. Aneman, A; Ewert, S; Fändriks, L; Laesser, M; Oi, Y, 2004)	0.93
"Treatment with candesartan, but not the combination of hydralazine and hydrochlorothiazide, significantly increased the expression of Cx37 and Cx40, although blood pressure decreased similarly."	( Angiotensin II receptor blockade corrects altered expression of gap junctions in vascular endothelial cells from hypertensive rats. Abe, I; Fujii, K; Goto, K; Iida, M; Kansui, Y; Nakamura, K; Oniki, H; Shibata, Y, 2004)	0.66
"Treatment with candesartan attenuated all of these changes and prevented significant albuminuria."	( Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Fan, Q; Gohda, T; Gu, L; Horikoshi, S; Kobayashi, M; Liao, J; Suzuki, Y; Tomino, Y; Wang, LN; Yamashita, M, 2004)	2.11
"Treatment with candesartan increased EB extravasation in the kidney in normovolaemic controls."	( Effects of candesartan and enalaprilat on the organ-specific microvascular permeability during haemorrhagic shock in rats. Binkowski, K; Dendorfer, A; Eichler, W; Klotz, KF; Puchakayala, MR; Schumacher, J, 2006)	1.06
"Pretreatment with candesartan before an acute MI improves global LV function, prevents LV dilation, and blunts the increase in constitutive microtubulin, with minimal effects on LV hemodynamics, regional function, or tissue endothelial nitric oxide synthase. "	( Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction. Castellano, L; Do, R; Gaballa, MA; Goldman, S; Juneman, E; Phan, H; Thai, H, 2006)	0.67
"Treatment with candesartan markedly increased mRNA expression of angiotensin II type-2 receptor and methyl methanesulfonate sensitive-2 in the brain in KK-A(y) mice, determined by quantitative RT-PCR."	( Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2007)	0.89
"Treatment with candesartan did not affect the levels of NT-proBNP."	( Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2009)	2.14
"Pretreatment with candesartan and ramipril (low dose) did not reduce blood pressure during MCAO, whereas ramipril high dose did. "	( Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. Krikov, M; Müller, S; Thone-Reineke, C; Unger, T; Villringer, A, 2008)	2.12
"Cotreatment with candesartan reversed the inhibitory effects of Ang II on the expression levels of these mRNAs."	( Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Goto, J; Inagaki, K; Kano, Y; Makino, H; Miyoshi, T; Ogura, T; Otani, H; Otsuka, F; Suzuki, J, 2008)	0.67
"Treatment with candesartan, pioglitazone, and their combination resulted in significantly reduced mRNA expression of the inflammatory markers CXCL1 and TNFalpha in vivo (P<0.01)."	( Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. Kintscher, U; Krikov, M; Müller, S; Schefe, JH; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A, 2008)	0.93
"Treatment with candesartan, 16 mg o.d., with or without hydrochlorothiazide, for 24 weeks, significantly reduced left ventricular mass and arterial hypertrophy in patients with hypertension. "	( Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. Shiels, A; Spratt, JC; Webb, DJ; Williams, B, 2001)	1.05

Excerpt	Reference	Relevance
" No serious or severe adverse events were reported."	( Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. Högemann, A; Hoogkamer, JF; Kirch, W; Kleinbloesem, CH; Nokhodian, A; Ouwerkerk, M; Weidekamm, E, 1998)	0.59
" We hypothesized that higher doses will be safe and well tolerated."	( Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Ashton, M; Weinberg, AJ; Weinberg, MS; Zappe, DH, )	0.13
"Candesartan was well tolerated with no serious drug-related adverse events reported."	( Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Ashton, M; Weinberg, AJ; Weinberg, MS; Zappe, DH, )	1.57
"The results of this pilot study suggest that supramaximal doses of ARBs are safe and well tolerated in patients with chronic kidney disease, while reducing both blood pressure and proteinuria."	( Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Ashton, M; Weinberg, AJ; Weinberg, MS; Zappe, DH, )	0.13
" The incidence of adverse events during both phases was comparably low and the results of laboratory tests were unremarkable."	( Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers. Ansari, A; Fuenfstueck, R; Hempel, RD; Klebs, S; Weidinger, G, )	0.13
"To evaluate the evidence for temporal reporting patterns, such as the Weber effect, in spontaneous post-marketing adverse event (AE) reports submitted to the Food and Drug Administration (FDA), for four members of the angiotensin II receptor blockers drug class (ARBs)."	( Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Dal Pan, GJ; Governale, LA; Hammad, TA; McAdams, MA; Swartz, L, 2008)	0.35
" Adverse events leading to drug discontinuation were more frequent in the candesartan group: placebo/candesartan risk (%), lowest compared with highest age category: hyperkalemia (0."	( Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. Cohen-Solal, A; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Puu, M; Solomon, SD; Swedberg, K; Yusuf, S, 2008)	0.89
"Older patients were at a greater absolute risk of adverse CV mortality and morbidity outcomes but derived a similar relative risk reduction and, therefore, a greater absolute benefit from treatment with candesartan, despite receiving a somewhat lower mean daily dose of candesartan."	( Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. Cohen-Solal, A; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Puu, M; Solomon, SD; Swedberg, K; Yusuf, S, 2008)	0.84
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
"5 mg candesartan would be safe in the rabbit eyes."	( Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model. Lee, JE; Lee, SM; Lim, DW; Oum, BS; Park, HJ; Shin, JH, 2011)	1.14
"The regular dose of an angiotensin II type-1 receptor blocker (ARB) in renal transplant patients for hypertension is shown to be safe and effective; however, information on the appropriate dosing of ARBs in renal transplant patients is limited."	( Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. Abe, T; Ichimaru, N; Imamura, R; Isaka, Y; Kawada, N; Kitamura, H; Kojima, Y; Kokado, Y; Moriyama, T; Nonomura, N; Okumi, M; Rakugi, H; Takahara, S, 2011)	0.61
"The gradual increase of an ARB to its maximal dose in renal transplant patients is safe when carefully monitored."	( Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. Abe, T; Ichimaru, N; Imamura, R; Isaka, Y; Kawada, N; Kitamura, H; Kojima, Y; Kokado, Y; Moriyama, T; Nonomura, N; Okumi, M; Rakugi, H; Takahara, S, 2011)	0.61
" A low dose of HCTZ in combination with candesartan reduces blood pressure effectively without adverse effects on the glucose and lipid profiles."	( Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Fujiwara, W; Ishii, J; Izawa, H; Kinoshita, K; Morimoto, S; Mukaide, D; Nomura, M; Ozaki, Y; Ukai, G; Yokoi, H, 2013)	0.66
" In the present analysis we aim to investigate the effect of change in blood pressure during the first 2 days of stroke on the risk of early adverse events and poor outcome."	( Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012)	0.38
" The primary effect parameter was early adverse events (recurrent stroke, stroke progression, and symptomatic hypotension) during the first 7 days, analyzed using logistic regression, with the group with a small decrease in SBP as the reference group."	( Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012)	0.38
" N/C combination demonstrated a lower incidence of vasodilatory adverse events than N monotherapy (18."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.75
"N/C combination was effective in participants with hypertension and showed an improved side effect profile compared with N monotherapy."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.75
" We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on adverse events: hospitalizations or emergency room consultations."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" Rates of adverse events for losartan, valsartan, and candesartan users (N=136 177) aged ≥66 years were calculated monthly, 24 months before and 12 months after generics commercialization."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.7
"Among generic users, immediate or delayed differences in adverse events rates were observed right after generic commercialization for 3 antihypertensive drugs."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" Rates of adverse events were similar for patients using and not using preventive medications."	( Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. Ailani, J; Baygani, S; Hundemer, HP; Krege, JH; Loo, LS; Port, M; Schim, J, 2019)	0.51

Excerpt	Reference	Relevance
"The pharmacokinetic parameters on days 1 and 7 revealed no statistically significant influence of liver impairment on the pharmacokinetics of candesartan."	( Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. Högemann, A; Hoogkamer, JF; Kirch, W; Kleinbloesem, CH; Nokhodian, A; Ouwerkerk, M; Weidekamm, E, 1998)	0.79
"Although serum trough levels increased during repeated administration and half-life was higher in patients with impaired renal function, candesartan cilexetil at a dose of 8 mg per day does not lead to drug accumulation in these patients."	( Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Buter, H; de Jong, PE; de Zeeuw, D; Navis, GY; Woittiez, AJ, 1999)	0.77
" No relevant pharmacokinetic drug-food or drug-drug interactions are known."	( Clinical pharmacokinetics of candesartan. Gleiter, CH; Mörike, KE, 2002)	0.61
" These pharmacodynamic differences warrant further investigation and clarification."	( Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. Belz, GG; Butzer, R; Kober, S; Mutschler, E, 2002)	0.54
" Finally, some relevant pharmacokinetics and metabolic properties of the database of 53 compounds are calculated using the VolSurf and MetaSite software to allow the simultaneous characterization of pharmacodynamic and pharmacokinetics properties of the chemical space of angiotensin II receptor antagonists."	( Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. Berellini, G; Cruciani, G; Mannhold, R, 2005)	0.33
" The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs."	( Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. Habuchi, T; Inoue, T; Kagaya, H; Miura, M; Ohkubo, T; Saito, M; Satoh, S; Suzuki, T, 2009)	0.63
" The half-life of candesartan was short in the vitreous, and modification of the delivery method would be required to extend the action duration for clinical applications."	( Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model. Lee, JE; Lee, SM; Lim, DW; Oum, BS; Park, HJ; Shin, JH, 2011)	0.96
" The method uses 100 µl plasma and covers the calibration range 1-160 ng/ml for CAN and 2-160 ng/ml for HCTZ for routine pharmacokinetic studies in humans."	( LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. Bharathi, DV; Chatki, PK; Hotha, KK; Satyanarayana, V; Venkateswarlu, V, 2012)	0.64
" The developed assay was applied to an oral pharmacokinetic study in humans."	( LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. Bharathi, DV; Chatki, PK; Hotha, KK; Satyanarayana, V; Venkateswarlu, V, 2012)	0.64
" CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3."	( Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Abad-Santos, F; Cabaleiro, T; López-Rodríguez, R; Novalbos, J; Ochoa, D; Prieto-Pérez, R; Román, M; Talegón, M; Wojnicz, A, 2013)	0.39
"Compared with control group and nephrotic group received enalapril alone respectively, Tmax of enalaprilat in nephrotic group received both enalapril and candesartan cilexetil prolonged about 21."	( The effect of candesartan on the pharmacokinetics of enalaprilat in nephrotic rats. Bi, BT; Lin, HB; Lin, T; Ma, AD; Xu, JP; Yang, XM; Yang, YB, 2012)	0.94
"Dietary sodium, the main determinant of the pharmacodynamic response to renin-angiotensin system blockade, influences the pharmacokinetics of various cardiovascular drugs."	( Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. Azizi, M; Blanchard, A; Charbit, B; Ezan, E; Funck-Brentano, C; Ménard, J; Peyrard, S; Wuerzner, G, 2013)	0.39
" Pharmacokinetic assessments were performed over 48 hours for candesartan in part 1 and 72 hours for amlodipine in part 2 after drug administration on Day 10."	( No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. Huh, W; Kim, JR; Kim, S; Ko, JW, 2018)	0.99
" The method was successfully applied to investigate pharmacokinetic interaction between PIT and CAN in wistar rats."	( Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction. Kothari, C; Patel, M, 2020)	0.82
" Repeat dose pharmacokinetic and pharmacodynamic study of the nano-fixed dose combination (FDC) was done in dexamethasone-induced animal model."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.56
" In pharmacokinetic analysis a sustained-release for 7 days was observed in nano-FDC group."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.56
" The present studies describe quality-by-design-based development and characterization of Candesartan loaded SNEDDS for improving its pharmacodynamic potential."	( Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential. Kaushik, D; Verma, R, 2020)	1.08

Excerpt	Reference	Relevance
"A randomized clinical trial was used to compare the effects of an angiotensin II type 1 receptor inhibitor, candesartan, singly or in combination with a reducing sodium diet, the DASH diet, on the quality of life (QOL) in outpatients with hypertension."	( Assessment of quality of life in a randomized clinical trial of candesartan only or in combination with DASH diet for hypertensive patients. Geleris, P; Kirpizidis, H; Stavrati, A, 2005)	0.78
"Angiotensin II type 1 receptor blockade with a therapeutic dosage of candesartan maintains significant control of blood pressure and may improve QOL-scores, especially when combined with a reducing sodium diet."	( Assessment of quality of life in a randomized clinical trial of candesartan only or in combination with DASH diet for hypertensive patients. Geleris, P; Kirpizidis, H; Stavrati, A, 2005)	0.8
"Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients."	( Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006)	0.88
" An ARB (candesartan, 4 mg/ day) in combination with an ACEI (enalapril, 5 mg/day) was started."	( Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation. Hosoi, G; Ikemiya, M; Ishii, T; Noma, H; Osugi, Y; Sako, M; Yamada, H, 2006)	1.1
" Pioglitazone monotherapy significantly attenuated cardiovascular p22(phox) and Rac1 in SHRSP, whereas pioglitazone combined with candesartan more attenuated p22(phox) and significantly reduced Nox1."	( Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008)	0.76
"Previous studies have shown highly effective lowering of blood pressure with thiazide diuretics in combination with angiotensin receptor blockers."	( Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Fujiwara, W; Ishii, J; Izawa, H; Kinoshita, K; Morimoto, S; Mukaide, D; Nomura, M; Ozaki, Y; Ukai, G; Yokoi, H, 2013)	0.39
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"To determine the bioequivalence of a nifedipine and candesartan fixed-dose combination (FDC) with the corresponding loose combination, and to investigate the pharmacokinetic drug-drug interaction potential between both drugs."	( Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Brendel, E; Dietrich, H; Froede, C; Thomas, D; Weimann, B, 2013)	0.87
" each drug alone, the 90% CIs remained within the range of 80 - 125% indicating the absence of a clinically relevant pharmacokinetic drug-drug interaction."	( Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Brendel, E; Dietrich, H; Froede, C; Thomas, D; Weimann, B, 2013)	0.62
" No clinically relevant pharmacokinetic drug-drug interaction between nifedipine and candesartan was observed."	( Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Brendel, E; Dietrich, H; Froede, C; Thomas, D; Weimann, B, 2013)	0.84
"To investigate the effect of low-dose carvedilol combined with candesartan in the prevention of acute and chronic cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast cancer."	( [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013)	0.88
"Forty patients were randomly divided into two groups: the experimental group with chemotherapy plus low-dose carvedilol combined with candesartan (20 cases) and control group with chemotherapy alone (20 cases)."	( [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013)	0.84
"The use of low-dose carvedilol combined with candesartan can reduce the acute and chronic cardiotoxicity of anthracycline drugs, and with tolerable toxicities."	( [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013)	0.9
" Hence, there is no evidence for a potential drug-drug interaction between PIT and CAN."	( Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction. Kothari, C; Patel, M, 2020)	0.82
" Candesartan in combination with RDN prolonged trough BP and attenuated renal hemodynamic responses to blood loss."	( Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage. Booth, LC; Denton, KM; Head, GA; May, CN; McArdle, Z; Moritz, KM; Schlaich, MP; Singh, RR, 2022)	1.63

Excerpt	Reference	Relevance
"In order to improve the oral bioavailability (BA) of 2-butyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimid azole - 7-carboxylic acid (3: CV-11194) and 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (4: CV-11974), novel angiotensin II (AII) receptor antagonists, chemical modification to yield prodrugs has been examined."	( Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. Furukawa, Y; Inada, Y; Kato, T; Kohara, Y; Kubo, K; Naka, T; Nishikawa, K; Shibouta, Y; Yoshimura, Y, 1993)	0.29
" This might be ascribed to their improved bioavailability by increased lipophilicity."	( Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. Imamiya, E; Inada, Y; Kohara, Y; Kubo, K; Naka, T; Wada, T, 1996)	0.29
" Oral bioavailability is low (about 40%) because of incomplete absorption."	( Clinical pharmacokinetics of candesartan. Gleiter, CH; Mörike, KE, 2002)	0.61
" Estrogen has been shown to downregulate angiotensin type 1 (AT1) receptor expression and to increase the bioavailability of endothelium-derived NO, which decreases AT1 receptor expression."	( Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. Harrison-Bernard, LM; Raij, L; Schulman, IH, 2003)	0.32
"Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the gastrointestinal tract, with insurmountable receptor binding abilities."	( Candesartan for the management of heart failure: more than an alternative. McKelvie, RS, 2006)	3.22
" Ang II receptor type 1 blocker candesartan or ACE inhibitor captopril markedly attenuated eNOS-derived O(2)(-) and hydrogen peroxide production while augmenting NO bioavailability in diabetic aortas, implicating recoupling of eNOS."	( Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Cai, H; Oak, JH, 2007)	0.62
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"Salt-sensitive (SS) hypertension is a vascular diathesis characterized by reduced cardiovascular and renal nitric oxide bioavailability and local upregulation of ANG II."	( Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. Jaimes, EA; Pearse, DD; Puzis, L; Raij, L; Zhou, MS, 2008)	0.35
"In addition to a class effect of ARBs, telmisartan may have additional effects on nitric oxide bioavailability and atherosclerotic change through its PPAR gamma-mediated effects in genetically hyperlipidemic rabbits."	( Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, H; Yoshida, K, 2008)	0.35
" An increase in production of superoxide anion and hydrogen peroxide, reduction of nitric oxide synthesis, and a decrease in bioavailability of antioxidants have been demonstrated in human hypertension."	( [Oxidative stress and mild hypertension]. Kurabayashi, M; Nakamura, T; Saito, Y, 2008)	0.35
" However, CC exhibited incomplete intestinal absorption with low oral bioavailability due to its poor aqueous solubility."	( Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. Bu, H; Gao, F; Gao, Z; Huang, Y; Li, Y; Shen, J; Zhang, Z; Zhao, C, 2011)	0.63
"The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug."	( Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation. Dohnal, J; Grunwaldova, V; Jampilek, J; Kral, V; Vaculikova, E, 2012)	0.73
" There was a marked decrease in nitric oxide (NO) bioavailability and antioxidant enzyme capacity."	( Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014)	0.66
" Generic drug equivalence is evaluated through comparative bioavailability studies."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
"9 fold in terms of bioavailability as compared to the pure drug."	( Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug. Fatima, Z; Kaur, CD; Nashik, SS; Rizvi, DA; Srivastava, D; Tulsankar, SL, 2019)	0.51
"The prepared cocrystal was found to be relatively more soluble than the pure drug and also showed an enhanced oral bioavailability as compared to the pure drug."	( Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug. Fatima, Z; Kaur, CD; Nashik, SS; Rizvi, DA; Srivastava, D; Tulsankar, SL, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The buccal mucosa has been extensively studied as an alternative route for drug delivery as it improves the bioavailability of drugs administered via the peroral route."	( Candesartan exhibits low intrinsic permeation capacity and affects buccal tissue viability and integrity: An ex vivo study in porcine buccal mucosa. Garcia-Tarazona, YM; Gordillo, JFI; Lafaurie, GI; Morantes, SJ; Ramos, FA; Sepúlveda, P, 2023)	2.35

Excerpt	Relevance	Reference
", the dose-response curve for angiotensin II was shifted to the right in a parallel manner, whereas the administration of higher doses resulted in nonparallel rightward shifts of the angiotensin II dose-response curves."	( Analysis of the effects of candesartan in the mesenteric vascular bed of the cat. Champion, HC; Kadowitz, PJ, 1997)	0.59
" Before and up to 24 h post dosing angiotensin II was infused in ascending dose steps until blood pressure (systolic and/or diastolic) increased by +25 mmHg."	( Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, B; Herrmann, V; Högemann, A; Magin, SG; Malerczyk, C; Mutschler, E; Roll, S; Voith, B, 1998)	0.54
" DR at 6-9 h post dosing reached a maximum of about 30 and at 24 h still amounted to 4-7, indicating the persistence of a relevant antagonistic effect in vivo."	( Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, B; Herrmann, V; Högemann, A; Magin, SG; Malerczyk, C; Mutschler, E; Roll, S; Voith, B, 1998)	0.54
" A moderate drug accumulation of 20%, which does not require a dose adjustment, was observed following once-daily dosing in both groups."	( Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. Högemann, A; Hoogkamer, JF; Kirch, W; Kleinbloesem, CH; Nokhodian, A; Ouwerkerk, M; Weidekamm, E, 1998)	0.59
" At this concentration, candesartan only produces a slight rightward shift of the angiotensin II dose-response curve."	( The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells. De Backer, JP; Fierens, FL; Vanderheyden, PM; Vauquelin, G, 1999)	0.96
", candesartan shifted the dose-response curve to AngII to the right in an insurmountable manner, indicating an insurmountable blockade of AT1 receptors."	( Analysis of the effects of candesartan on responses to angiotensin II in the hindquarters vascular bed of the cat. Bivalacqua, TJ; Champion, HC; Kadowitz, PJ; Lambert, DG; McNamara, DB, 1999)	1.32
" At the lowest dose studied (20 microgram/kg iv), the inhibitory effects of candesartan were competitive, whereas at the highest dose (100 microgram/kg iv) the dose-response curve for angiotensin II was shifted to the right in a nonparallel manner with inhibitory effects that could not be surmounted."	( Role of AT(1) receptors and autonomic nervous system in mediating acute pressor responses to ANG II in anesthetized mice. Bivalacqua, TJ; Champion, HC; Dalal, A; Kadowitz, PJ, 1999)	0.53
" Data are reviewed to demonstrate that ACE escape reflects inadequate ACE dosage rather than a decrease in ACE inhibition occurring with time."	( Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Berlowitz, M; Ennezat, PV; Le Jemtel, TH; Sonnenblick, EH, 2000)	0.31
" h(-1)) was found at the 4- to 8-hour interval after dosing in a subset of subjects (n=5) who received the 16-mg dose 4 hours earlier than the other subjects."	( Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Fisher, ND; Hollenberg, NK; Lansang, MC; Osei, SY; Price, DA, 2000)	0.54
" Dose-response curves for drinking response to intracerebroventricular injections of ANG II were compared between SD and TG rats."	( Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN). Bader, M; Böhm, M; Bricca, G; Ganten, D; Monti, J; Schinke, M, 2001)	0.31
" To investigate blockade of postsynaptic AT1 receptors, we studied the effect of the AT1 antagonists on dose-response curves elicited by exogenous Ang II."	( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001)	0.51
" Interestingly, the greatest doses of the AT1 antagonists caused less than maximal reduction in the stimulation-induced increase in DBP, resulting in a U-shaped dose-response relationship."	( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001)	0.51
" In this study we investigated the importance of drug dosing in mediating these differences by comparing the AT(1)-receptor blockade induced by 3 doses of valsartan with that obtained with 3 other antagonists at given doses."	( Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Brunner, HR; Burnier, M; Centeno, C; Maillard, MP; Nussberger, J; Würzner, G, 2002)	0.31
" The response rate of monotherapy with candesartan in patients with hypertension increases with dosage, but never exceeds 60% at a daily dosage of 16mg of candesartan."	( Clinical pharmacokinetics of candesartan. Gleiter, CH; Mörike, KE, 2002)	0.88
" In this study, we examined the relative contribution of non-ACE pathways, by comparing the response to candesartan and to captopril at the top of the dose-response in normal humans when in balance on a low-salt, as well as a high-salt, diet."	( Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. Fisher, ND; Hollenberg, NK; Lansang, MC; Osei, SY; Price, DA, 2001)	0.53
" Chronic candesartan therapy, 16 mg once-daily effectively suppresses pressor responses to Ang II over the duration of the dosing interval."	( The effects of candesartan on vascular responses to angiotensin II and norepinephrine in normal volunteers. Howes, L; Phoon, S; Tran, D, 2001)	1.08
" The authors established with an initial dose-response curve using escalating concentrations of CN that 10 nmol/L abrogated vasoconstriction induced by angiotensin II (0."	( Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade. Jugdutt, BI; Kumar, D; Moudgil, R; Musat-Marcu, S; Xu, Y, 2002)	0.31
" The authors established with an initial dose-response curve using escalating concentrations of CN that 10 nmol/L abrogated vasoconstriction induced by angiotensin II (0."	( Increased AT(2)R protein expression but not increased apoptosis during cardioprotection induced by AT(1)R blockade. Jugdutt, BI; Kumar, D; Moudgil, R; Musat-Marcu, S; Xu, Y, 2002)	0.31
" The selected studies were included in a meta-analysis of the dose-response relationship for each drug."	( The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Elmfeldt, D; Meredith, P; Olofsson, B, 2002)	0.31
"There was a wide range of changes in RPF and GFR in response to the two agents, each administered at the top of its dose-response range."	( Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Fisher, ND; Gordon, MS; Hollenberg, NK; Laffel, LM; Lansang, MC; Perkins, B; Price, DA; Williams, GH, 2003)	0.32
" Further research is necessary to determine which AT1RBs and which dosing regimens are optimal."	( Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. Mancini, GB, 2002)	0.31
" While the biphenyltetrazole compound candesartan dissociated slowly and behaved as an insurmountable antagonist for WT-AT(1), it dissociated swiftly and only produced a rightward shift of the angiotensin Ang II- and -IV dose-response curves for inositol phosphate (IP) accumulation in cells expressing N111G."	( Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors. Hunyady, L; Kersemans, V; Le, MT; Szaszák, M; Vanderheyden, PM; Vauquelin, G, 2003)	0.59
" score of test increased) after repeated dosing of the drug, although the subjects did not notice such changes."	( Subclinical alteration of taste sensitivity induced by candesartan in healthy subjects. Araki, N; Fujimura, A; Harada, K; Nishiki, K; Sugimoto, K; Tsuruoka, S; Wakaumi, M, 2004)	0.57
"These data suggest that candesartan subclinically reduces taste sensitivity after repeated dosing in healthy subjects."	( Subclinical alteration of taste sensitivity induced by candesartan in healthy subjects. Araki, N; Fujimura, A; Harada, K; Nishiki, K; Sugimoto, K; Tsuruoka, S; Wakaumi, M, 2004)	0.88
" Patients received candesartan titrated to a targeted dosage of 160 mg/day (5 times above the currently approved maximum dose) and remained at that dosage for the subsequent 4 weeks."	( Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Ashton, M; Weinberg, AJ; Weinberg, MS; Zappe, DH, )	0.46
" This study demonstrates the need to further investigate the optimal dosing strategy for ARBs in reducing the progression of renal disease."	( Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Ashton, M; Weinberg, AJ; Weinberg, MS; Zappe, DH, )	0.13
" Dose-response curves were established for the noradrenaline-induced (10(-12) to 10(-7) mol/kg) increase of diastolic blood pressure in pithed rats treated with tubocurarine, propranolol, and atropine."	( Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Dendorfer, A; Dominiak, P; Raasch, W; Ziegler, A, 2004)	0.32
" Dosage was doubled at week 4 and hydrochlorothiazide was added at week 12 if blood pressure response was inadequate."	( Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Stumpe, KO, 2004)	0.32
"Angiotensin II type 1 receptor blockade with a therapeutic dosage of candesartan maintains significant control of blood pressure and may improve QOL-scores, especially when combined with a reducing sodium diet."	( Assessment of quality of life in a randomized clinical trial of candesartan only or in combination with DASH diet for hypertensive patients. Geleris, P; Kirpizidis, H; Stavrati, A, 2005)	0.8
" Furthermore, because of the notorious subtarget dosing of such agents in clinical practice, we explored the influence of a modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type 1 receptor blockers, and the combination on common biologic markers of coronary atherosclerotic disease."	( Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination. Cox, CD; Meyerrose, GE; Peek, MC; Seifert, CF; Simoni, JS; Tsikouris, JP, 2006)	0.33
"This study of various methods of the renin-angiotensin system inhibition in stable coronary atherosclerotic disease patients demonstrates negligible effects of a modest dosing of ramipril and the combination of ramipril plus candesartan on common biologic markers of coronary atherosclerotic disease."	( Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination. Cox, CD; Meyerrose, GE; Peek, MC; Seifert, CF; Simoni, JS; Tsikouris, JP, 2006)	0.52
" Patients' dosing histories were compiled electronically (MEMS, AARDEX)."	( Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ. Mengden, T; Tousset, E; Uen, S; Vetter, H, 2006)	0.53
" Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)."	( Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007)	0.87
" Models were adjusted for demographic, clinical, physician, and hospital characteristics; models were also adjusted for dosage categories, which were represented by time-dependent variables."	( Angiotensin II receptor blockers for the treatment of heart failure: a class effect? Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV, 2007)	0.34
" It compared the antihypertensive effect between increasing ARB dosage and the addition of controlled-release nifedipine."	( [NICE-Combi study: effect of nifedipine in combination with an angiotensin II receptor blocker on BP control and renal protection]. Hasebe, N, 2006)	0.33
" The authors randomly assigned 269 patients who had persistent proteinuria (> or =1 g/d) despite 7 wk of treatment with the highest approved dosage of candesartan (16 mg/d) to 16, 64, or 128 mg/d candesartan for 30 wk."	( Supramaximal dose of candesartan in proteinuric renal disease. Burgess, E; Chiu, A; Muirhead, N; Pichette, V; Rene de Cotret, P; Tobe, S, 2009)	0.87
"To describe the antihypertensive dose-response of combination therapy with candesartan and hydrochlorothiazide (HCT)."	( A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. Elmfeldt, D; Karlson, BW; Olofsson, B; Zetterstrand, S, 2009)	0.88
" An E(max) model was used to describe the placebo-adjusted dose-response surface for systolic and diastolic blood pressure (BP) reductions."	( A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. Elmfeldt, D; Karlson, BW; Olofsson, B; Zetterstrand, S, 2009)	0.65
" At baseline and after each dosing period, blood pressure measurements and 24-hour urine collections were obtained."	( Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study. Clifton, GD; LaSalle, BK; Saha, SA; Short, RA; Tuttle, KR, )	0.39
" Because administration of candesartan at appropriate dosage (4-12 mg/day) significantly decreased self-measured morning home BP, candesartan might possess the property to maintain a sustained BP reduction for up to 24 hours after dosing, and might be able to prevent early morning cardiovascular events."	( [Evaluation of antihypertensive effect of angiotensin II receptor blockers in patients with essential hypertension by self-measured home blood pressure--HACARARE 300 study]. Msanobu, T, 2009)	0.65
"To study the impact of the dosing time of an angiotensin II receptor blocker (ARB) titrated by self-measured home blood pressure (HBP) on cardiorenal damage in hypertensives."	( Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2010)	0.36
" Individuals were then randomly allocated to receive bedtime dosing or awakening dosing of candesartan (+/- diuretic as needed) titrated to achieve a target systolic HBP less than 135 mmHg."	( Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2010)	0.58
"In HBP-guided antihypertensive treatment in hypertensives, bedtime dosing of an ARB may be superior to awakening dosing for reducing microalbuminuria."	( Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2010)	0.36
"The regular dose of an angiotensin II type-1 receptor blocker (ARB) in renal transplant patients for hypertension is shown to be safe and effective; however, information on the appropriate dosing of ARBs in renal transplant patients is limited."	( Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. Abe, T; Ichimaru, N; Imamura, R; Isaka, Y; Kawada, N; Kitamura, H; Kojima, Y; Kokado, Y; Moriyama, T; Nonomura, N; Okumi, M; Rakugi, H; Takahara, S, 2011)	0.61
"In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which was an open-label multicenter trial to compare bedtime or awakening dosing of candesartan (+ diuretics as needed) among individuals with home SBP higher than 135 mmHg, we evaluated 254 hypertensive patients who underwent ambulatory BP monitoring, and measured their BNP at baseline and after 6th month of treatment."	( Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2012)	0.58
" In view of these findings, we should lower dosage and prolong dosing interval for nephrotic patients in the combination of enalapril and candesartan."	( The effect of candesartan on the pharmacokinetics of enalaprilat in nephrotic rats. Bi, BT; Lin, HB; Lin, T; Ma, AD; Xu, JP; Yang, XM; Yang, YB, 2012)	0.94
" The purpose of this research was to inform selection of an appropriate pre-specified primary dose-response analysis to demonstrate drug efficacy in a registration trial."	( Improper selection of a pre-specified primary dose-response analysis delays regulatory drug approval. Gobburu, J; Jadhav, P; Liu, J; Wang, Y, 2013)	0.39
"49 healthy, white, male subjects received: 60 mg nifedipine and 32 mg candesartan FDC, the loose combination of 60 mg nifedipine GITS and 32 mg candesartan, 60 mg nifedipine GITS alone, or 32 mg candesartan alone in a randomized, non-blinded, 4-period, 4-way crossover design with each dosing following overnight fasting."	( Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Brendel, E; Dietrich, H; Froede, C; Thomas, D; Weimann, B, 2013)	0.85
" When comparing AUC(0-tlast) and Cmax of nifedipine and candesartan after dosing with the loose combination vs."	( Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Brendel, E; Dietrich, H; Froede, C; Thomas, D; Weimann, B, 2013)	0.86
" Individual-level linkage of nationwide registries of hospitalization and drug dispensing in Denmark was used to describe patterns of ARB prescriptions and estimate dosage before and after November 2010."	( Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM, 2014)	0.4
"DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) aimed to determine the dose-response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.97
" A positive dose-response was observed, with all combinations providing statistically better blood pressure (BP) reductions from baseline versus respective monotherapies (P < 0."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.75
"In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which compared bedtime or awakening dosing of candesartan (+diuretics as needed) among subjects with home systolic BP (SBP) higher than 135 mm Hg, we evaluated 180 hypertensive patients who successfully underwent pulse wave analysis by HEM-9000AI and measured their urinary albumin/creatinine ratio (UACR) and left ventricular mass index (LVMI) (n = 144) at baseline and after 6 months of treatment."	( Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. Eguchi, K; Hoshide, S; Ishikawa, J; Kario, K; Shimizu, M; Yano, Y, 2015)	0.63
" The methods were successfully determined the three components in bulk powder, laboratory-prepared mixtures, and combined dosage forms."	( Mean centering of ratio spectra and concentration augmented classical least squares in a comparative approach for quantitation of spectrally overlapped bands of antihypertensives in formulations. Abdel Monem Hegazy, M; Fayez, YM, 2015)	0.42
" Treatments were administered for 12 weeks without dosage adjustment."	( A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. Cha, GS; Cha, TJ; Chae, SC; Chun, KJ; Hong, GR; Hur, SH; Hwang, JY; Kim, DI; Kim, DS; Kim, KS; Kim, MH; Lee, JH; Lee, SG; Yang, DH, 2016)	0.73
" Although the pharmacology of ROMK channels is still being developed, channel inhibitors have been identified and shown to cause natriuresis and diuresis, in the absence of any significant kaliuresis, on acute oral dosing to rats or dogs."	( The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype. Alonso-Galicia, M; Corona, A; Felix, JP; Garcia, ML; Gill, C; Hampton, C; Kaczorowski, GJ; Kohler, M; Liu, J; Metzger, JM; Ormes, J; Owens, K; Pai, LY; Pasternak, A; Price, O; Priest, BT; Rasa, C; Roy, S; Shah, K; Sullivan, KA; Tang, H; Thomas-Fowlkes, B; Tong, V; Xiao, J; Zhou, X, 2016)	0.43
"For both candesartan and amlodipine, the 90% confidence intervals for the geometric mean ratios of area under the concentration-time curve from time zero to the time of dosing interval of 24 hours and maximum concentration after drug administration fell within the bioequivalence acceptance criteria."	( No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. Huh, W; Kim, JR; Kim, S; Ko, JW, 2018)	1.17
"Three breastfeeding mothers, all stabilized on candesartan (8-32 mg/d), provided milk and plasma samples over one dosing interval (24 hours)."	( Transfer of Candesartan Into Human Breast Milk. Coberger, ED; Dalrymple, JM; Jensen, BP, 2019)	1.15
" Once weekly oral dosing of nano-FDC of amlodipine, CNDT and hydrochlorothiazide provided adequate antihypertensive effect which was not statistically different from daily dosing of free drugs in dexamethasone-induced animal model."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.56
"Once weekly oral dosing of nano-FDC of amlodipine, CNDT and hydrochlorothiazide provided adequate antihypertensive effect and was not statistically different from daily dosing of free drugs in dexamethasone-induced animal model."	( Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020)	0.56
" Considering these factors, a more individualized approach of candesartan dosing should be investigated in patients with HF."	( Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. Bonnefois, G; de Denus, S; Dubé, MP; Kassem, I; Li, J; Nekka, F; Rouleau, JL; Sanche, S; Tardif, JC; Turgeon, J; White, M, 2021)	1.15

Role	Description
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
angiotensin receptor antagonist	A hormone antagonist that blocks angiotensin receptors.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
benzimidazolecarboxylic acid	A member of the class of benzimidazoles carrying a carboxy group at unspecified position.
biphenylyltetrazole	A member of the class of biphenyls that consists of a biphenyl ring system substituted by a tetrazole ring at an unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Candesartan Action Pathway	7	4

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	13.8029	0.0025	41.7960	15,848.9004	AID1347398
USP1 protein, partial	Homo sapiens (human)	Potency	22.3872	0.0316	37.5844	354.8130	AID504865
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	13.8029	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	27.3189	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	0.0191	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	25.3735	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.1064	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1259401
pregnane X nuclear receptor	Homo sapiens (human)	Potency	15.8489	0.0054	28.0263	1,258.9301	AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	1.1509	0.0002	29.3054	16,493.5996	AID743069; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	0.0195	0.0010	8.3798	61.1304	AID1645840
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	35.4813	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	31.0399	0.0003	23.4451	159.6830	AID743065; AID743067
geminin	Homo sapiens (human)	Potency	13.3359	0.0046	11.3741	33.4983	AID624296
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	36.1254	0.0056	12.3677	36.1254	AID624032
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	3.2769	0.0000	0.5369	10.0000	AID625184
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	IC50 (µMol)	5.9472	0.0001	0.5453	10.0000	AID625186
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	3.0652	0.0004	1.8773	10.0000	AID625207
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	Ki	3.0398	0.0032	2.2887	9.3160	AID625207
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	9.0000	0.0001	1.7536	10.0000	AID625251
Adenosine receptor A3	Homo sapiens (human)	IC50 (µMol)	1.2199	0.0000	1.8940	8.5470	AID625196
Adenosine receptor A3	Homo sapiens (human)	Ki	0.6895	0.0000	0.9306	10.0000	AID625196
60 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1700	4.5590	10.0000	AID1594139
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	3.0000	0.0000	2.8005	10.0000	AID625248
Beta-3 adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	4.3000	0.0023	3.2415	8.0600	AID625206
Beta-3 adrenergic receptor	Homo sapiens (human)	Ki	3.2000	0.0030	2.3098	6.0450	AID625206
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.2199	0.0002	1.8742	10.0000	AID625196
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.6895	0.0001	0.9490	10.0000	AID625196
Alpha-2B adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	3.8430	0.0000	1.2380	8.1590	AID625202
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	1.7544	0.0002	0.7257	10.0000	AID625202
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	0.0006	0.0001	0.7396	10.0000	AID37529
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	3.0652	0.0008	1.5416	20.0000	AID625207
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	3.0398	0.0003	1.4656	10.0000	AID625207
Thromboxane-A synthase	Homo sapiens (human)	IC50 (µMol)	3.0594	0.0009	1.2304	10.0000	AID625229
Type-1 angiotensin II receptor	Homo sapiens (human)	IC50 (µMol)	0.0405	0.0002	0.0932	3.6000	AID1289936; AID1289942; AID568897
Type-1 angiotensin II receptor	Homo sapiens (human)	Ki	0.0070	0.0002	0.1837	4.7000	AID1289936; AID1352010
Type-1 angiotensin II receptor	Oryctolagus cuniculus (rabbit)	Ki	0.0006	0.0002	1.1828	4.7000	AID37529
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.2199	0.0000	1.8194	10.0000	AID625196
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.6895	0.0000	0.9650	10.0000	AID625196
Type-2 angiotensin II receptor	Homo sapiens (human)	Ki	10.0000	0.0002	0.5650	7.7790	AID1277889
10 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1700	4.5590	10.0000	AID1594139
Thiosulfate sulfurtransferase	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0600	3.9631	9.7000	AID1594135
60 kDa chaperonin	Escherichia coli	IC50 (µMol)	175.0000	0.0390	3.5552	9.8000	AID1594140; AID1594141
10 kDa chaperonin	Escherichia coli	IC50 (µMol)	175.0000	0.0390	3.5552	9.8000	AID1594140; AID1594141
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	Kd	0.0032	0.0000	0.0027	0.0100	AID412478
Leukotriene B4 receptor 2	Homo sapiens (human)	EC50 (µMol)	15.0000	0.0700	1.9375	6.8000	AID1779666
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Type-1 angiotensin II receptor	Homo sapiens (human)	Affinity	0.0001	0.0005	0.0315	0.2300	AID243379
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
MAPK cascade	Epidermal growth factor receptor	Homo sapiens (human)
ossification	Epidermal growth factor receptor	Homo sapiens (human)
embryonic placenta development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
hair follicle development	Epidermal growth factor receptor	Homo sapiens (human)
translation	Epidermal growth factor receptor	Homo sapiens (human)
signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
activation of phospholipase C activity	Epidermal growth factor receptor	Homo sapiens (human)
salivary gland morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
midgut development	Epidermal growth factor receptor	Homo sapiens (human)
learning or memory	Epidermal growth factor receptor	Homo sapiens (human)
circadian rhythm	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
diterpenoid metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
cerebral cortex cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell growth	Epidermal growth factor receptor	Homo sapiens (human)
lung development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of superoxide anion generation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
response to cobalamin	Epidermal growth factor receptor	Homo sapiens (human)
response to hydroxyisoflavone	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to reactive oxygen species	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of protein catabolic process	Epidermal growth factor receptor	Homo sapiens (human)
vasodilation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ovulation cycle	Epidermal growth factor receptor	Homo sapiens (human)
hydrogen peroxide metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
tongue development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA repair	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA replication	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of bone resorption	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Epidermal growth factor receptor	Homo sapiens (human)
regulation of JNK cascade	Epidermal growth factor receptor	Homo sapiens (human)
symbiont entry into host cell	Epidermal growth factor receptor	Homo sapiens (human)
protein autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
astrocyte activation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Epidermal growth factor receptor	Homo sapiens (human)
digestive tract morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
neuron projection morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
protein insertion into membrane	Epidermal growth factor receptor	Homo sapiens (human)
response to calcium ion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of glial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Epidermal growth factor receptor	Homo sapiens (human)
eyelid development in camera-type eye	Epidermal growth factor receptor	Homo sapiens (human)
response to UV-A	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of mucus secretion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to amino acid stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to cadmium ion	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to xenobiotic stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
liver regeneration	Epidermal growth factor receptor	Homo sapiens (human)
cell-cell adhesion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein kinase C activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of prolactin secretion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of cardiocyte differentiation	Epidermal growth factor receptor	Homo sapiens (human)
neurogenesis	Epidermal growth factor receptor	Homo sapiens (human)
multicellular organism development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of protein phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
heart development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuromuscular junction development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
motor neuron axon guidance	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
Schwann cell development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell growth	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of microtubule-based process	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
immature T cell proliferation in thymus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
negative regulation of immature T cell proliferation in thymus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of Rho protein signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
intracellular signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-ERBB4 signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
wound healing	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
myelination	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of MAP kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of translation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of angiogenesis	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell adhesion	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase I	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
oligodendrocyte differentiation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cellular response to growth factor stimulus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
semaphorin-plexin signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of protein targeting to membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neurogenesis	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of MAPK cascade	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
negative regulation of apoptotic process	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
multicellular organism development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell population proliferation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuron differentiation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
protein folding	60 kDa chaperonin	Escherichia coli K-12
response to radiation	60 kDa chaperonin	Escherichia coli K-12
response to heat	60 kDa chaperonin	Escherichia coli K-12
virion assembly	60 kDa chaperonin	Escherichia coli K-12
chaperone cofactor-dependent protein refolding	60 kDa chaperonin	Escherichia coli K-12
protein refolding	60 kDa chaperonin	Escherichia coli K-12
chaperone cofactor-dependent protein refolding	60 kDa chaperonin	Escherichia coli K-12
response to heat	60 kDa chaperonin	Escherichia coli K-12
inflammatory response	Adenosine receptor A3	Homo sapiens (human)
signal transduction	Adenosine receptor A3	Homo sapiens (human)
activation of adenylate cyclase activity	Adenosine receptor A3	Homo sapiens (human)
regulation of heart contraction	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A3	Homo sapiens (human)
response to wounding	Adenosine receptor A3	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell migration	Adenosine receptor A3	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Adenosine receptor A3	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A3	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A3	Homo sapiens (human)
adhesion of symbiont to host	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
'de novo' protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to unfolded protein	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to cold	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interferon-alpha production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-10 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-12 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-6 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein refolding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell proliferation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of macrophage activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isotype switching to IgG isotypes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein stabilization	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
chaperone-mediated protein complex assembly	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein maturation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
biological process involved in interaction with symbiont	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cellular response to interleukin-7	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein import into mitochondrial intermembrane space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial unfolded protein response	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apoptotic mitochondrial changes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
receptor-mediated endocytosis	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
carbohydrate metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Beta-3 adrenergic receptor	Homo sapiens (human)
energy reserve metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-3 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-3 adrenergic receptor	Homo sapiens (human)
eating behavior	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-3 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-3 adrenergic receptor	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of blood pressure	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
prostaglandin biosynthetic process	Thromboxane-A synthase	Homo sapiens (human)
icosanoid metabolic process	Thromboxane-A synthase	Homo sapiens (human)
cyclooxygenase pathway	Thromboxane-A synthase	Homo sapiens (human)
intracellular chloride ion homeostasis	Thromboxane-A synthase	Homo sapiens (human)
response to ethanol	Thromboxane-A synthase	Homo sapiens (human)
positive regulation of vasoconstriction	Thromboxane-A synthase	Homo sapiens (human)
response to fatty acid	Thromboxane-A synthase	Homo sapiens (human)
regulation of cell growth	Type-1 angiotensin II receptor	Homo sapiens (human)
kidney development	Type-1 angiotensin II receptor	Homo sapiens (human)
renin-angiotensin regulation of aldosterone production	Type-1 angiotensin II receptor	Homo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensin	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Type-1 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Type-1 angiotensin II receptor	Homo sapiens (human)
Rho protein signal transduction	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of vasoconstriction	Type-1 angiotensin II receptor	Homo sapiens (human)
calcium-mediated signaling	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of phospholipase A2 activity	Type-1 angiotensin II receptor	Homo sapiens (human)
low-density lipoprotein particle remodeling	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of renal sodium excretion	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin-activated signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of cell population proliferation	Type-1 angiotensin II receptor	Homo sapiens (human)
symbiont entry into host cell	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of protein metabolic process	Type-1 angiotensin II receptor	Homo sapiens (human)
cell chemotaxis	Type-1 angiotensin II receptor	Homo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
blood vessel diameter maintenance	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of CoA-transferase activity	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Type-1 angiotensin II receptor	Homo sapiens (human)
inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
blood vessel remodeling	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by circulatory renin-angiotensin	Type-2 angiotensin II receptor	Homo sapiens (human)
angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure	Type-2 angiotensin II receptor	Homo sapiens (human)
brain renin-angiotensin system	Type-2 angiotensin II receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger	Type-2 angiotensin II receptor	Homo sapiens (human)
brain development	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of blood pressure	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of heart rate	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of cell growth	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of metanephros size	Type-2 angiotensin II receptor	Homo sapiens (human)
exploration behavior	Type-2 angiotensin II receptor	Homo sapiens (human)
nitric oxide-cGMP-mediated signaling	Type-2 angiotensin II receptor	Homo sapiens (human)
angiotensin-activated signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
vasodilation	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of neurotrophin TRK receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
neuron apoptotic process	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of metanephric glomerulus development	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of branching involved in ureteric bud morphogenesis	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
inflammatory response	Type-2 angiotensin II receptor	Homo sapiens (human)
osteoblast differentiation	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to unfolded protein	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
chaperone cofactor-dependent protein refolding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sulfur amino acid catabolic process	Thiosulfate sulfurtransferase	Homo sapiens (human)
cyanate catabolic process	Thiosulfate sulfurtransferase	Homo sapiens (human)
epithelial cell differentiation	Thiosulfate sulfurtransferase	Homo sapiens (human)
rRNA import into mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
rRNA transport	Thiosulfate sulfurtransferase	Homo sapiens (human)
chemotaxis	Leukotriene B4 receptor 2	Homo sapiens (human)
negative regulation of adenylate cyclase activity	Leukotriene B4 receptor 2	Homo sapiens (human)
keratinocyte migration	Leukotriene B4 receptor 2	Homo sapiens (human)
leukotriene signaling pathway	Leukotriene B4 receptor 2	Homo sapiens (human)
neuropeptide signaling pathway	Leukotriene B4 receptor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
growth factor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
RNA polymerase I core binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
transmembrane signaling receptor activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
signaling receptor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ATP binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
coreceptor activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
receptor tyrosine kinase binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
identical protein binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ErbB-3 class receptor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein heterodimerization activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
magnesium ion binding	60 kDa chaperonin	Escherichia coli K-12
protein binding	60 kDa chaperonin	Escherichia coli K-12
ATP binding	60 kDa chaperonin	Escherichia coli K-12
isomerase activity	60 kDa chaperonin	Escherichia coli K-12
ATP hydrolysis activity	60 kDa chaperonin	Escherichia coli K-12
identical protein binding	60 kDa chaperonin	Escherichia coli K-12
unfolded protein binding	60 kDa chaperonin	Escherichia coli K-12
ATP-dependent protein folding chaperone	60 kDa chaperonin	Escherichia coli K-12
G protein-coupled adenosine receptor activity	Adenosine receptor A3	Homo sapiens (human)
lipopolysaccharide binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
p53 binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
DNA replication origin binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
single-stranded DNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
double-stranded RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
high-density lipoprotein particle binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isomerase activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP hydrolysis activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
enzyme binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ubiquitin protein ligase binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein A-I binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP-dependent protein folding chaperone	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
norepinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta3-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-3 adrenergic receptor binding	Beta-3 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-3 adrenergic receptor	Homo sapiens (human)
epinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monooxygenase activity	Thromboxane-A synthase	Homo sapiens (human)
thromboxane-A synthase activity	Thromboxane-A synthase	Homo sapiens (human)
iron ion binding	Thromboxane-A synthase	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	Thromboxane-A synthase	Homo sapiens (human)
heme binding	Thromboxane-A synthase	Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activity	Thromboxane-A synthase	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Thromboxane-A synthase	Homo sapiens (human)
angiotensin type I receptor activity	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin type II receptor activity	Type-1 angiotensin II receptor	Homo sapiens (human)
protein binding	Type-1 angiotensin II receptor	Homo sapiens (human)
bradykinin receptor binding	Type-1 angiotensin II receptor	Homo sapiens (human)
protein heterodimerization activity	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin type II receptor activity	Type-2 angiotensin II receptor	Homo sapiens (human)
protein binding	Type-2 angiotensin II receptor	Homo sapiens (human)
receptor antagonist activity	Type-2 angiotensin II receptor	Homo sapiens (human)
RNA binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding chaperone	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
metal ion binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
thiosulfate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
5S rRNA binding	Thiosulfate sulfurtransferase	Homo sapiens (human)
3-mercaptopyruvate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
leukotriene receptor activity	Leukotriene B4 receptor 2	Homo sapiens (human)
leukotriene B4 receptor activity	Leukotriene B4 receptor 2	Homo sapiens (human)
G protein-coupled peptide receptor activity	Leukotriene B4 receptor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
semaphorin receptor complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
nucleus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
nucleoplasm	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
early endosome	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cytosol	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
endosome membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
basolateral plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
apical plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuromuscular junction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ruffle membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
presynaptic membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
myelin sheath	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
perinuclear region of cytoplasm	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB3:ERBB2 complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
receptor complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
basal plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
cytoplasm	60 kDa chaperonin	Escherichia coli K-12
cytosol	60 kDa chaperonin	Escherichia coli K-12
membrane	60 kDa chaperonin	Escherichia coli K-12
GroEL-GroES complex	60 kDa chaperonin	Escherichia coli K-12
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A3	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Adenosine receptor A3	Homo sapiens (human)
dendrite	Adenosine receptor A3	Homo sapiens (human)
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
synapse	Adenosine receptor A3	Homo sapiens (human)
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytoplasm	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrion	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
early endosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytosol	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
clathrin-coated pit	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cell surface	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
coated vesicle	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
secretory granule	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm midpiece	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
migrasome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-containing complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
lipopolysaccharide receptor complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-3 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
endoplasmic reticulum	Thromboxane-A synthase	Homo sapiens (human)
endoplasmic reticulum membrane	Thromboxane-A synthase	Homo sapiens (human)
cytosol	Thromboxane-A synthase	Homo sapiens (human)
plasma membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-2 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-2 angiotensin II receptor	Homo sapiens (human)
mitochondrion	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular space	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrial matrix	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
nucleoplasm	Leukotriene B4 receptor 2	Homo sapiens (human)
plasma membrane	Leukotriene B4 receptor 2	Homo sapiens (human)
membrane	Leukotriene B4 receptor 2	Homo sapiens (human)
plasma membrane	Leukotriene B4 receptor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID26234	Bioavailability determined from the ratio of AUC(plasma) for 0 to infinity after oral dosing of the test compound (10 mg/kg) to intravenous administration of CD-11194 (1 mg/kg) in rats	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214222	Cmax in men plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214117	Tmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1737434	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as maximal activation at 10 uM measured after 39 hrs by dual luciferase reporter assay relative to pioglitazo	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID237981	Percentage modification of drug adsorbed after administration to human	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1594140	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1487370	Binding affinity to human AT1 receptor expressed in CHO cells assessed as dissociation rate constant at 1.5 nM incubated for 60 mins followed by compound washout in presence of losartan	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID364008	Antagonist activity at AT1 receptor in rat aorta	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
AID1214133	Clearance in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1594137	Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1487382	Binding affinity to human AT1 receptor expressed in CHO cells assessed as residence time at 1.5 nM incubated for 60 mins followed by compound washout in presence of losartan	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID181931	Percent inhibition of angiotensin II (0.1 ug/kg iv) -induced pressor response 3h after administration of test compounds (1 mg/kg po) in conscious male Sprague-Dawley rats	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID247116	Maximal effect against human Angiotensin II receptor type 1	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID37516	Inhibitory activity against Angiotensin II receptor, type 1 in rabbit aorta	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1487364	Displacement of [3H]-candesartan from human AT1 receptor expressed in CHO cells assessed as dissociation rate constant at 1.5 nM pre-incubated with cells followed by compound washout and subsequent addition of [3H]-candesartan up to 60 mins	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID239885	pKa value against human Angiotensin II receptor type 1	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1214128	Clearance in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214129	AUC in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1594145	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID243379	Binding affinity for AT1 receptor	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1487362	Antagonist activity at human AT1 receptor expressed in CHO cells assessed as reduction in angiotensin 2-induced inositol phosphate accumulation by measuring dissociation rate constant preincubated with cells followed by compound washout in presence of los	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1214111	Half life in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID185269	Percent inhibition of the Angiotensin-II (0.1ug/kg, iv) induced pressor response after 3 hours of administration (1 mg/kg po) in rats	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1214099	AUC in human plasma expressing CYP2C81/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1487375	Antagonist activity at human AT1 receptor expressed in CHO cells assessed as reduction in angiotensin 2-induced inositol phosphate accumulation by measuring residence time constant preincubated with cells followed by compound washout in presence of losart	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1214118	Clearance in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1214122	Tmax in human plasma expressing CYP2C91/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1487380	Binding affinity to human AT1 receptor expressed in CHO cells assessed as residence time at 1.5 nM incubated for 60 mins followed by compound washout	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1214104	AUC in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID27862	Total clearance value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID39791	Relative binding affinity of compound to Angiotensin II receptor, type 1 was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID183920	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 24 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID181935	Percent inhibition of AII (0.1 ug/kg iv) -induced pressor response at 7 hr after administration of test compounds (0.1 mg/kg po) in conscious male Sprague-Dawley rats.	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID1214126	Half life in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214127	Tmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1214119	AUC in human plasma expressing CYP2C91/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID185267	Percent inhibition of the Angiotensin-II (0.1micro g/kg, iv) induced pressor response after 7 hours of administration (3 mg/kg po) in rats	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1594141	Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1487363	Antagonist activity at human AT1 receptor expressed in CHO cells assessed as reduction in angiotensin 2-induced inositol phosphate accumulation by measuring dissociation rate constant preincubated with cells followed by compound washout and subsequent add	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID185264	Percent inhibition of the Angiotensin-II (0.1micro g/kg, iv) induced pressor response after 7 hours of administration (10 mg/kg po) in rats	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1214102	Tmax in human plasma expressing CYP2C81/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1594134	Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID167803	Concentration required for inhibition of Angiotensin-II induced rabbit aorta strips contraction	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1352010	Displacement of [125I-Sar1-Ile8]-Ang2 from human angiotensin 2 receptor type 1 receptor expressed in HEK293 cells after 1 hr by gamma counting analysis	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID1214131	Half life in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1737440	Modulation of cell death in imatinib-resistant human K562 cells assessed by increase in imatinib-mediated cell death in presence of presence of imatinib measured after 72 hrs by Propidium iodide stain based FACS assay (Rvb = 17%)	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID412478	Antagonist activity at AT1 receptor in rat aortic rings	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists.
AID1214156	Clearance in men plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214100	Cmax in human plasma expressing CYP2C81/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1277889	Binding affinity to type-2 angiotensin-2 receptor (unknown origin)	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
AID39038	Inhibition of specific binding of [125 I ] Angiotensin-II (0.2 nM) to bovine adrenal cortex	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1487374	Antagonist activity at human AT1 receptor expressed in CHO cells assessed as reduction in angiotensin 2-induced inositol phosphate accumulation by measuring residence time constant preincubated with cells followed by compound washout and subsequent additi	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1594135	Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID679591	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Candesartan: 50 uM) in MDR1-expressing LLC-PK1 cells	2002	Life sciences, Feb-15, Volume: 70, Issue:13	Interaction of digoxin with antihypertensive drugs via MDR1.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID167359	Inhibitory activity against angiotensin II type 1 induced contractions in rabbit aorta	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1487376	Displacement of [3H]-candesartan from human AT1 receptor expressed in CHO cells assessed as residence time at 1.5 nM pre-incubated with cells followed by compound washout and subsequent addition of [3H]-candesartan up to 60 mins	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID185393	Percent inhibition of the Angiotensin-II (0.1ug/kg, iv) induced pressor response after 7 hours of administration (1 mg/kg po) in rats	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1289936	Displacement of [3H]-Asp-{Nomega-[N-(4-propanoylaminobutyl)aminocarbonyl]}Arg-ValTyr-Ile-His-Pro-Phe-OH Tris(hydrotrifluoroacetate) from human AT1 receptor transfected in CHO cells co-expressing Galpha16-mtAEQ after 2 hrs by liquid scintillation counting	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
AID1214109	AUC in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID37529	Inhibitory activity against Angiotensin II receptor, type 1 in rat adrenal membrane	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214116	Half life in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214157	Clearance in women plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214106	Half life in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214110	Cmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID237099	Time required for elimination of 50% of the compound	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1214120	Cmax in human plasma expressing CYP2C91/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1594139	Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID568897	Binding affinity to angiotensin AT1 receptor	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1214121	Half life in human plasma expressing CYP2C91/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1737435	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as intrinsic activity measured after 39 hrs by dual luciferase reporter assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1737443	Cytotoxicity against human HS5 cells assessed as cell death at 10 uM measured after 72 hrs by Propidium iodide stain based FACS analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID26605	pka value was determined	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID185270	Percent inhibition of the Angiotensin-II (0.1ug/kg, iv) induced pressor response after 3 hours of administration (3 mg/kg po) in rats	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1737436	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 10 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1594144	Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID568789	Antagonist activity at angiotensin AT1 receptor	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1214224	Half life in men plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214123	Clearance in human plasma expressing CYP2C91/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID183922	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 5 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39652	Inhibition against Angiotensin II receptor, type 1	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1214107	Tmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214101	Half life in human plasma expressing CYP2C81/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID27037	Half life of compound was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1214124	AUC in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214113	Clearance in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID183921	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 3 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID1214221	AUC in women plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1277888	Displacement of 125I-[Sar1,Leu8] angiotensin-2 from rat type 1 angiotensin-2 receptor expressed in African green monkey COS7 cells after 24 hrs	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
AID1214223	Cmax in women plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214155	Tmax in women plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214220	AUC in men plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID183923	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 7 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID184050	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 1 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID184209	Inhibitory effect on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 0.5 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID185262	Percent inhibition of the Angiotensin-II (0.1micro g/kg, iv) induced pressor response after 3 hours of administration (10 mg/kg po) in rats	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
AID1214125	Cmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID568918	Ratio of compound Ki to losartan Ki for angiotensin AT1 receptor	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID364010	Antihypertensive activity against desoxycortisone-induced hypertension in rat assessed as decrease in mean arterial blood pressure at 5 mg/kg, ip	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
AID412480	Antihypertensive effect in desoxycortisone acetate-induced hypertensive rat assessed as maximum decrease in mean arterial blood pressure at 5 mg/kg, ip after 6 hrs	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists.
AID1214153	Half life in women plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1779666	Agonist activity at human BLT2 overexpressed in CHO-K1 cells assessed as accumulation of inositol monophosphate measured after 90 mins by HTRF assay	2021	ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8	Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.
AID1487369	Binding affinity to human AT1 receptor expressed in CHO cells assessed as dissociation rate constant at 1.5 nM incubated for 60 mins followed by compound washout	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1692293	Inhibition of ADP-stimulated human platelet aggregation assessed as ADP light transmission at 50 uM preincubated for 5 min followed by ADP stimulation by light transmission aggregometry (Rvb = 62 +/- 3%)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1214103	Clearance in human plasma expressing CYP2C81/1 polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID239874	Competitive antagonism of Angiotensin II receptor in endothelium removed isolated rat aortic ring; (n = 5)	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists.
AID1289942	Displacement of [3H]-Angiotensin 2 from human AT1 receptor transfected in CHOK1 cells preincubated for 30 mins with bovine serum albumin followed by radioligand addition by liquid scintillation counting	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
AID39039	Inhibition of specific binding of [125I]angiotensin II (0.2 nM) to angiotensin II receptor in bovine adrenal cortex	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID23686	Partition coefficient (logP)	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID1214114	AUC in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214105	Cmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID29138	Acid dissociation value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID237841	Oral bioavailability	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID183919	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 2 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1214132	Tmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1737437	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 20 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1214154	Tmax in men plasma at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1487372	Binding affinity to human AT1 receptor expressed in CHO cells assessed as dissociation rate constant at 1.5 nM incubated for 60 mins measured after isotopic dilution	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1216814	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID16032	Bioavailability	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID1214130	Cmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214108	Clearance in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214115	Cmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214112	Tmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 32 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID242919	Competitive antagonism of Angiotensin II receptor in endothelium removed isolated rat aortic ring	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists.
AID1487384	Binding affinity to human AT1 receptor expressed in CHO cells assessed as residence time at 1.5 nM incubated for 60 mins measured after isotopic dilution	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID23918	Renal clearance value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346995	Human AT1 receptor (Angiotensin receptors)	1999	British journal of pharmacology, Feb, Volume: 126, Issue:4	Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
AID1346995	Human AT1 receptor (Angiotensin receptors)	1999	European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3	Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	164 (8.71)	18.2507
2000's	1020 (54.17)	29.6817
2010's	601 (31.92)	24.3611
2020's	98 (5.20)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	412 (21.36%)	5.53%
Reviews	180 (9.33%)	6.00%
Case Studies	67 (3.47%)	4.05%
Observational	6 (0.31%)	0.25%
Other	1,264 (65.53%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (161)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension [NCT01289132]	Phase 2	926 participants (Actual)	Interventional	2007-07-31	Completed
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke [NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C [NCT03770936]	Phase 3	45 participants (Anticipated)	Interventional	2018-10-01	Recruiting
Influence of Blockade of the Renin-angiotensin System for Preservation of Cognitive Function, Hormonal Counter-regulatory Response, Symptomatology and Cardiac Repolarisation During Hypoglycaemia in Patients With Type 1 Diabetes [NCT01116180]		9 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb) [NCT01135212]	Phase 3	290 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled [NCT02368665]	Phase 3	180 participants (Actual)	Interventional	2014-12-31	Completed
A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled [NCT02368652]	Phase 3	181 participants (Actual)	Interventional	2014-12-31	Completed
Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation [NCT01162902]	Phase 4	150 participants (Anticipated)	Interventional	2013-09-30	Not yet recruiting
Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence [NCT01227603]	Phase 1	49 participants (Actual)	Interventional	2010-11-30	Completed
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers [NCT02646982]	Phase 2	77 participants (Actual)	Interventional	2016-06-30	Completed
"A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a Real-liFe GP sEtting in Sweden" [NCT00620178]		14,000 participants (Anticipated)	Observational	2008-03-31	Completed
Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan and the Loose Combination of Both Components and to Investigate the Bioequivalence Between the Fixed [NCT01350609]	Phase 1	49 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Amlodipine Between Free Combination of Amlodipine and Candesartan and Amlodipine Monotherapy in Healthy Male Volunteers [NCT02064556]	Phase 1	24 participants (Actual)	Interventional	2014-05-31	Completed
A Randomized, Double-blind, Multi-center, PhaseⅡ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Candesartan Cilexetil and Amlodipine Besylate for the Dose Selection in Patients With Essential Hypertension [NCT02059616]	Phase 2	384 participants (Anticipated)	Interventional	2014-02-28	Recruiting
An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Candesartan 32 mg and Rosuvastatin 20 mg in Healthy Male Volunteers [NCT02079506]	Phase 1	40 participants (Actual)	Interventional	2014-02-28	Completed
Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomize [NCT03136666]	Phase 1	12 participants (Actual)	Interventional	2010-04-19	Completed
DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy. [NCT00252720]	Phase 3	1,850 participants (Actual)	Interventional	2001-08-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control [NCT02521233]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Refe [NCT02094924]	Phase 1	16 participants (Actual)	Interventional	2014-04-17	Completed
The Effect of Continuing or Discontinuing ACE-I/ARBs Therapy on the Incidence of Contrast-induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Coronary Angiography; a Randomized Controlled Trial [NCT05271448]		600 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02186496]	Phase 1	32 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Candesartan Between Free Combination of Candesartan and Amlodipine and Candesartan Monotherapy in Healthy Male Volunteers [NCT02064621]	Phase 1	24 participants (Actual)	Interventional	2014-06-30	Completed
Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety Following Administration of CJ-30059 and Co-administration of Candesartan Cilexetil and Amlodipine Besylate in Healthy Volunteers. [NCT02173912]	Phase 1	32 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control [NCT02521246]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI. [NCT01052272]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2005-07-31	Completed
A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension [NCT01025843]	Phase 1	20 participants (Actual)	Interventional	2009-12-01	Completed
Angiotensin Receptor Blockade an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C [NCT00930995]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Not Awarded)
Single Dose Crossover Comparative Bioavailability Study of Candesartan Cilexetil 32 mg Tablets in Healthy Adult Subjects Under Fasting Conditions [NCT04012307]	Phase 1	40 participants (Actual)	Interventional	2019-07-11	Completed
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02801526]	Phase 1	32 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets [NCT03847506]	Phase 4	127 participants (Actual)	Interventional	2018-07-05	Completed
A Randomized, Double-blind, Multi-center, Phase 2 Trial to Evaluate the Efficacy and Safety of Candesartan/Amlodipine Combined or Alone and Select Better Dose of CKD-330 in Patients With Essential Hypertension [NCT02206165]	Phase 2	456 participants (Anticipated)	Interventional	2014-03-31	Recruiting
A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients With Essential Hypertension [NCT01303783]	Phase 2	1,381 participants (Actual)	Interventional	2011-04-30	Completed
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease [NCT04394117]	Phase 4	787 participants (Actual)	Interventional	2020-06-19	Completed
An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Cande [NCT02254447]	Phase 1	18 participants (Actual)	Interventional	2014-12-02	Completed
A Multicenter, Double-blind, Controlled, Randomized Trial to Evaluate the Association Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension [NCT05920005]	Phase 3	698 participants (Anticipated)	Interventional	2023-08-22	Recruiting
Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension [NCT01012479]	Phase 4	107 participants (Actual)	Interventional	2009-10-31	Completed
A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Sy [NCT00391846]	Phase 4	252 participants (Actual)	Interventional	2006-10-31	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
The Precision Hypertension Care Study [NCT02774460]	Phase 4	280 participants (Actual)	Interventional	2017-02-20	Completed
Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function [NCT00634400]	Phase 3	6,268 participants (Anticipated)	Interventional	1999-03-31	Completed
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function [NCT00634712]	Phase 3	734 participants (Anticipated)	Interventional	1999-06-30	Completed
A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R208 (Candesartan Cilexetil and Rosuvastatin Calcium Fixed Dose Combinations) in Comparison to Each Component Administered Alone in Healthy Male Volunteers [NCT02707224]	Phase 1	40 participants (Actual)	Interventional	2015-01-31	Completed
Randomized, Controlled, Parallel Arm, PROBE Study to Evaluate Different Effects of Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension [NCT00644475]	Phase 3	60 participants (Anticipated)	Interventional	2008-03-31	Recruiting
CandeSpartan Study Candesartan Spanish Response-prediction and Tolerability Study Observational Study on Response Predictors and Tolerability of Candesartan in Usual Clinical Practice [NCT04138316]		85 participants (Actual)	Observational [Patient Registry]	2020-01-02	Completed
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02811731]	Phase 1	32 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy [NCT02651870]	Phase 3	135 participants (Actual)	Interventional	2015-04-22	Completed
A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HC [NCT00434967]	Phase 3	2,207 participants (Actual)	Interventional	2007-01-31	Completed
Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study [NCT00884663]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2009-04-30	Completed
A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA) [NCT03640312]	Phase 2	62 participants (Actual)	Interventional	2019-08-30	Active, not recruiting
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine in a Combination Package Compared to the Separate Intake of the Reference Brands Atacand and Splendil After a Fasting Period. [NCT00905333]	Phase 1	36 participants (Actual)	Interventional	2008-10-31	Completed
Does Telmisartan Compared to Candesartan Due to a Distinctly Larger Volume of Distribution Exert Stronger Effects in Relevant Peripheral Tissues, e.g. Renal and Adrenal Tissues [NCT02261116]	Phase 4	24 participants (Actual)	Interventional	2002-04-30	Completed
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV) [NCT00679484]	Phase 3	400 participants (Anticipated)	Interventional	2008-06-30	Terminated(stopped due to Lack of subject recruitment)
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France [NCT00679640]		450 participants (Actual)	Observational	2008-01-31	Completed
[NCT02614352]	Phase 1	60 participants (Anticipated)	Interventional		Not yet recruiting
The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves [NCT00699452]	Phase 3	120 participants (Anticipated)	Interventional	2009-05-31	Recruiting
[NCT02609711]	Phase 1	90 participants (Anticipated)	Interventional	2015-11-30	Active, not recruiting
"Candesartan Added Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Inv [NCT00775840]	Phase 3	22 participants (Actual)	Interventional	2008-01-31	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
A Single Dose, 2-Period, Cross-over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil [NCT00844324]	Phase 1	36 participants (Actual)	Interventional	2009-03-31	Completed
Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function [NCT00843154]	Phase 3	571 participants (Actual)	Interventional	2005-12-31	Terminated(stopped due to Insufficient enrollment)
Effects of Telmisartan Compared With Candesartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients: a Multi-center, Prospective, Randomized, Open-labeled, Blinded Endpoints Trial [NCT00863980]		1,500 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Principle investigator resigned in 2013)
A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy [NCT00573430]	Phase 4	128 participants (Actual)	Interventional	2007-12-31	Completed
Open Label, Comparative, Multiple-dose, Fixed-sequence Steady State Trial in Healthy Volunteers to Assess the Pharmacokinetic Interaction of Candesartan, Atorvastatin and Amlodipine After a Multiple Oral Dose Administration [NCT04245046]	Phase 1	18 participants (Actual)	Interventional	2019-01-18	Completed
An Open-label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: a Long Term Study [NCT00690612]	Phase 3	35 participants (Actual)	Interventional	2007-09-30	Completed
Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 m [NCT00621153]	Phase 4	214 participants (Actual)	Interventional	2008-02-29	Completed
Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine [NCT00564057]	Phase 4	30 participants (Anticipated)	Interventional	2007-09-30	Recruiting
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]	Phase 4	2,400 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Double-blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous ß-blocker or Calcium Channel Blocker [NCT00775814]	Phase 4	188 participants (Actual)	Interventional	2006-10-31	Completed
Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients [NCT01992796]	Phase 3	300 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects With Essential Hypertension Who Are Inadequately Co [NCT02047019]	Phase 3	0 participants (Actual)	Interventional	2017-12-01	Withdrawn(stopped due to GPDC decided to terminate the study)
Bariatric Surgery and Pharmacokinetics Candesartan: BAR-MEDS Candesartan [NCT03460327]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy. [NCT00252733]	Phase 3	5,238 participants (Actual)	Interventional	2001-06-30	Completed
Characterization of Vascular Effects of Candesartan and Pioglitazone. [NCT00154037]		40 participants	Interventional	2005-10-31	Completed
Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1) [NCT00538486]	Phase 4	360 participants (Actual)	Interventional	2008-02-29	Completed
Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy. [NCT00252694]	Phase 3	4,717 participants (Actual)	Interventional	2001-08-31	Completed
A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy [NCT00348686]	Phase 4	315 participants (Actual)	Interventional	2006-06-30	Completed
A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to S [NCT00242346]	Phase 3	270 participants	Interventional	2003-04-30	Completed
[NCT00360763]	Phase 4	600 participants	Interventional		Recruiting
An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 8mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 8mg Reference Tablet of Candesartan Cilexetil (Atacand) in He [NCT02006589]	Phase 1	16 participants (Actual)	Interventional	2013-12-11	Completed
An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 16mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 16mg Reference Tablet of Candesartan Cilexetil (Atacand) in [NCT02006602]	Phase 1	16 participants (Actual)	Interventional	2013-12-13	Completed
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? [NCT04606563]	Phase 3	341 participants (Actual)	Interventional	2020-10-09	Terminated(stopped due to DSMC recommendation due to futility)
Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial [NCT00990639]	Phase 1/Phase 2	85 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunt [NCT02548286]	Phase 1	53 participants (Actual)	Interventional	2015-08-31	Completed
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia. [NCT02770261]	Phase 3	219 participants (Actual)	Interventional	2015-12-31	Completed
DP-R208 Pharmacokinetic Study Phase I [NCT02709187]	Phase 1	37 participants (Actual)	Interventional	2016-03-31	Completed
The Renin-angiotensin System (RAS) in Barrett's Esophagus as Future Biomarkers for Dysplasia and Cancer? A Randomized Controlled Trial [NCT02879721]	Early Phase 1	33 participants (Actual)	Interventional	2009-10-31	Completed
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function [NCT00634309]	Phase 3	597 participants (Anticipated)	Interventional	1999-06-30	Completed
Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients [NCT00541853]	Phase 4	150 participants (Anticipated)	Interventional	2007-12-31	Not yet recruiting
Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study [NCT00430833]	Phase 2	0 participants	Interventional		Active, not recruiting
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothi [NCT00867490]	Phase 3	186 participants (Actual)	Interventional	2009-03-31	Completed
Angiotensin-II Blockade in Mitral Regurgitation [NCT00587470]	Phase 4	60 participants (Actual)	Interventional	1998-08-31	Completed
ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs [NCT00192803]	Phase 4	20 participants	Interventional		Not yet recruiting
Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab [NCT00459771]	Phase 3	210 participants (Actual)	Interventional	2007-06-30	Completed
Heart Outcomes Prevention Evaluation-3 [NCT00468923]	Phase 4	12,705 participants (Actual)	Interventional	2007-05-31	Completed
[NCT01629225]	Phase 4	500 participants (Anticipated)	Interventional	2013-07-31	Recruiting
Genetic Epidemiology of Responses to Antihypertensives [NCT00005520]		1,200 participants (Actual)	Observational	1997-02-28	Completed
Neurohumoral and Oxidative Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Essential Hypertensive Patients. [NCT00232882]	Phase 4	86 participants (Actual)	Interventional	2003-12-31	Completed
A 36 Week Three-Center Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo [NCT00282178]	Phase 2	26 participants (Actual)	Interventional	2005-04-30	Completed
Scandinavian Candesartan Acute Stroke Trial [NCT00120003]	Phase 3	2,500 participants (Anticipated)	Interventional	2005-06-30	Completed
Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis - Effect of Blockade of the Angiotensin-II Receptor [NCT00294775]	Phase 3	140 participants (Anticipated)	Interventional	2006-02-28	Active, not recruiting
A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2 Study to Evaluate the Dose-response Relationship of the Efficacy and Safety of Oral Administration of TAK-272 in Patients With Type 2 Diabetes Mellitus and Mi [NCT02332824]	Phase 2	415 participants (Actual)	Interventional	2014-10-16	Completed
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients [NCT00125463]	Phase 3	3,200 participants	Interventional	2001-09-30	Active, not recruiting
Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation [NCT00139386]	Phase 4	1,119 participants (Actual)	Interventional	2005-10-31	Completed
[NCT00154050]		22 participants	Interventional	2004-05-31	Completed
A Pilot, Proof of Concept, Placebo-controlled Trial of Candesartan as an Adjunctive Treatment for Bipolar Depression [NCT04430959]	Early Phase 1	0 participants (Actual)	Interventional	2020-10-01	Withdrawn(stopped due to The reason the study was withdrawn was due to lack of funds. In addition, the PI is moving to a different institution and it would not be feasible to proceed with the study under these circumstances.)
Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study [NCT00184587]	Phase 2	40 participants (Actual)	Interventional	2005-03-31	Completed
Non-interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or add-on Therapy. [NCT00573742]		1,940 participants (Actual)	Observational	2007-09-30	Completed
A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension [NCT02944734]	Phase 2	392 participants (Actual)	Interventional	2014-09-30	Completed
[NCT00530595]		0 participants	Interventional		Completed
Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms [NCT00400582]	Phase 4	300 participants (Anticipated)	Interventional	2006-11-30	Completed
A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate [NCT00383929]	Phase 3	1,979 participants (Actual)	Interventional	2006-09-30	Completed
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) [NCT00108706]	Phase 4	50 participants	Interventional	2004-12-31	Active, not recruiting
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
The Renin-Angiotensin System in Essential Hypertension [NCT00141583]		11 participants (Anticipated)	Interventional	2004-04-30	Terminated(stopped due to Insufficient accrual rate)
An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers [NCT01806311]	Phase 1	34 participants (Anticipated)	Interventional	2012-12-31	Completed
A Phase-3 Randomized, Double-Blind, Parallel-Group Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine (8/5 mg) in Chinese Subjects With Mild/Moderate Essential Hypertension, Who Do Not Achieve Target Blood Press [NCT02969265]	Phase 3	0 participants (Actual)	Interventional	2017-05-09	Withdrawn(stopped due to Business reasons unrelated to product safety)
[NCT00130975]	Phase 3	200 participants	Interventional	2001-04-30	Completed
Danish Hypertension Prevention Project [NCT00150631]	Phase 3	100 participants (Actual)	Interventional	2000-11-30	Active, not recruiting
A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period. [NCT00244621]	Phase 3	95 participants (Actual)	Interventional	2004-11-30	Completed
Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function [NCT01678794]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2012-02-29	Completed
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study [NCT00235287]	Phase 4	60 participants (Anticipated)	Interventional	2005-09-30	Recruiting
A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System [NCT00288717]		300 participants	Interventional	2006-02-28	Recruiting
Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study [NCT00320970]		36 participants	Interventional	2002-08-31	Completed
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury [NCT05826912]	Phase 2	672 participants (Anticipated)	Interventional	2024-03-29	Not yet recruiting
Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB [NCT00328302]	Phase 4	13 participants	Interventional	2000-09-30	Active, not recruiting
Effects of Sodium Intake on Pharmacokinetic/Pharmacodynamic Relationship of a Single Dose of a Renin Angiotensin System-Blocker, or a Beta-Blocker in Normotensive Sodium-Depleted or Replated Volunteers in a Cross-Over Study [NCT00310778]	Phase 1	64 participants (Actual)	Interventional	2006-03-31	Completed
Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial. [NCT01734096]	Phase 4	78 participants (Actual)	Interventional	2009-05-31	Completed
Renin-Angiotensin-System Quantification in Patients Treated With Aliskiren or Candesartan (RASQAL) [NCT01827202]	Phase 4	24 participants (Actual)	Interventional	2012-12-31	Completed
Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate in Healthy Male Volunteers. [NCT01845272]	Phase 1	40 participants (Anticipated)	Interventional	2013-04-30	Active, not recruiting
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty [NCT04743063]		40,000 participants (Anticipated)	Observational	2021-01-14	Active, not recruiting
A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) [NCT04351724]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2020-04-16	Recruiting
Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression [NCT01794455]	Phase 4	1 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Enrollment difficulties)
The Effect of Multidisciplinary Intervention on Patients With Persistent Post-traumatic Headache [NCT05328635]		100 participants (Anticipated)	Observational	2021-09-01	Recruiting
An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers. [NCT02988362]	Phase 1	40 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Adiposity and Endothelin Receptor Function [NCT03583866]	Early Phase 1	25 participants (Actual)	Interventional	2018-05-21	Active, not recruiting
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol [NCT01434134]	Phase 2	130 participants (Actual)	Interventional	2011-09-30	Completed
Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension [NCT01444833]		35 participants (Anticipated)	Interventional	2008-10-31	Recruiting
An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 [NCT05122182]	Phase 2	49 participants (Actual)	Interventional	2022-01-07	Terminated(stopped due to Withdrawal of funding support from the trial funder.)
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg) [NCT04574713]	Phase 2	450 participants (Anticipated)	Interventional	2020-04-26	Recruiting
"Unisia Combination Tablets LD, HD Special Drug Use Surveillance Hypertension: Long-Term Use" [NCT02068495]		3,409 participants (Actual)	Observational	2010-06-15	Completed
An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence [NCT01062451]	Phase 1	80 participants (Actual)	Interventional	2009-05-31	Completed
"Early Treatment With Candesartan vs Placebo in Asymptomatic Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)" [NCT05321875]	Phase 3	320 participants (Anticipated)	Interventional	2022-06-02	Recruiting
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial [NCT01611077]	Phase 4	88 participants (Actual)	Interventional	2012-01-31	Completed
Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial [NCT01613209]	Phase 3	83 participants (Actual)	Interventional	2011-12-31	Completed
"A Randomized, Double Blind, Cross-Over, Placebo-Controlled Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism, of Non Diabetic, Non Hypertensive Subjects With Dysglycemia and Abdominal Obesity.ARAMIA" [NCT00319202]	Phase 4	56 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Difficulties in completing the required sample size)
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX) [NCT01984164]	Phase 2	176 participants (Actual)	Interventional	2014-08-20	Completed
ECARD Combination Tablets LD&HD Special Drug Use Surveillance: Long-term Use (12 Months) [NCT02016183]		3,222 participants (Actual)	Observational	2009-04-01	Completed
Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients [NCT00356395]	Phase 4	40 participants	Interventional	2003-08-31	Completed
Strain-based vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention Strategy in Patients With Breast Cancer Who Treated With Adjuvant Trastuzumab [NCT04429633]		136 participants (Anticipated)	Interventional	2019-07-19	Recruiting
An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers [NCT01926652]	Phase 1	34 participants (Actual)	Interventional	2013-07-31	Completed
The RAS, Fibrinolysis and Cardiopulmonary Bypass [NCT00607672]	Phase 4	111 participants (Actual)	Interventional	2006-08-31	Completed
Pilot Study, Single-blind, Candesartan Versus Usual Care of Peripheral Neuropathy Development Induced by Vincristine (PNIV) in Patients Treated for Lymphoma B [NCT03688633]	Phase 2	9 participants (Actual)	Interventional	2019-05-01	Terminated(stopped due to Patient Recruitment Failure)
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combina [NCT00360178]	Phase 3	198 participants (Actual)	Interventional	2006-07-31	Completed
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial) [NCT00605072]	Phase 2	53 participants (Actual)	Interventional	2008-01-31	Completed
Pilot Study of Candesartan: An Angiotensin Receptor Blocker as a Treatment for Cocaine Dependence [NCT01938664]	Phase 2	30 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Results of interim efficacy analysis showed results were not promising.)
A Randomised, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Oral Doses of Candesartan Cilexetil in Healthy Subjects [NCT01976572]	Phase 1	18 participants (Actual)	Interventional	2013-10-31	Completed
Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects With Moderate to Severe Essential Hypertension [NCT01788358]	Phase 3	508 participants (Actual)	Interventional	2013-02-14	Completed
"Candesartan Cilexetil Tablets Specified Drug-use Survey Hypertension: Survey on Patients With Metabolic Syndrome" [NCT02166697]		14,151 participants (Actual)	Observational	2006-06-30	Completed
Blopress Tablets Special Drug Use Surveillance 「Challenge - Quality Control」 [NCT02211638]		18,113 participants (Actual)	Observational	2011-06-13	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00244621 (4) [back to overview]	Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28
NCT00244621 (4) [back to overview]	Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)
NCT00244621 (4) [back to overview]	Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP)
NCT00244621 (4) [back to overview]	Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28
NCT00252694 (4) [back to overview]	Number of Participants With at Least a 3 Step Improvement or a Persistent 2-step Improvement in the ETDRS Severity Scale.
NCT00252694 (4) [back to overview]	Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).
NCT00252694 (4) [back to overview]	Rate of Change in Urinary Albumin Excretion Rate (UAER).
NCT00252694 (4) [back to overview]	Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale
NCT00252720 (4) [back to overview]	Rate of Change in Urinary Albumin Excretion Rate (UAER).
NCT00252720 (4) [back to overview]	Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale
NCT00252720 (4) [back to overview]	Number of Participants With a Regression of Diabetic Retinopathy.
NCT00252720 (4) [back to overview]	Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).
NCT00252733 (2) [back to overview]	Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.
NCT00252733 (2) [back to overview]	Rate of Change in Urinary Albumin Excretion Rate (UAER).
NCT00348686 (6) [back to overview]	Change of Diastolic Blood Pressure (DBP)
NCT00348686 (6) [back to overview]	Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine
NCT00348686 (6) [back to overview]	Change of Systolic Blood Pressure (SBP)
NCT00348686 (6) [back to overview]	LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index
NCT00348686 (6) [back to overview]	Percent Change of B Type Natriuretic Peptides (BNP) Level
NCT00348686 (6) [back to overview]	Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only
NCT00391846 (8) [back to overview]	Number of CV Deaths
NCT00391846 (8) [back to overview]	Changes in Health-related Quality of Life
NCT00391846 (8) [back to overview]	Discontinuations
NCT00391846 (8) [back to overview]	Total Number of Titration Steps in Prescribed Heart Failure Treatment
NCT00391846 (8) [back to overview]	Changes in NT-proBNP Values Over Time in All Patients
NCT00391846 (8) [back to overview]	Changes in Heart Failure Symptoms
NCT00391846 (8) [back to overview]	Number of Days in Hospital for CV Reason
NCT00391846 (8) [back to overview]	Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)
NCT00434967 (3) [back to overview]	Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).
NCT00434967 (3) [back to overview]	The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study
NCT00434967 (3) [back to overview]	Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks)
NCT00573430 (5) [back to overview]	The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks
NCT00573430 (5) [back to overview]	Treatment-emergent Adverse Events
NCT00573430 (5) [back to overview]	Change of Systolic and Diastolic Blood Pressure From Baseline
NCT00573430 (5) [back to overview]	Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation
NCT00573430 (5) [back to overview]	Inflammatory Marker (Hs-C-peptide Reactive Protein)
NCT00605072 (5) [back to overview]	Blood Pressure Outcome: Systolic BP
NCT00605072 (5) [back to overview]	Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall
NCT00605072 (5) [back to overview]	Cognitive Assessment: Forward Digit Span Test
NCT00605072 (5) [back to overview]	Cognitive Assessment: Trail Making Test Part B
NCT00605072 (5) [back to overview]	Blood Flow Velocity, Sitting
NCT00607672 (13) [back to overview]	Interleukin-6 (IL-6) Response
NCT00607672 (13) [back to overview]	Plasminogen Activator Inhibitor-1 (PAI-1) Response
NCT00607672 (13) [back to overview]	Interleukin-10 (IL-10) Response
NCT00607672 (13) [back to overview]	Interleukin-8 (IL-8) Response
NCT00607672 (13) [back to overview]	Tissue-type Plasminogen Activator (t-PA) Antigen Response
NCT00607672 (13) [back to overview]	Vasopressor Drug Use
NCT00607672 (13) [back to overview]	Stroke
NCT00607672 (13) [back to overview]	Re-exploration for Bleeding
NCT00607672 (13) [back to overview]	New Onset Atrial Fibrillation
NCT00607672 (13) [back to overview]	Blood Loss
NCT00607672 (13) [back to overview]	Acute Kidney Injury
NCT00607672 (13) [back to overview]	Length of Hospital Stay
NCT00607672 (13) [back to overview]	Blood Product Transfusion Requirement
NCT00621153 (1) [back to overview]	Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy
NCT00690612 (2) [back to overview]	Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP).
NCT00690612 (2) [back to overview]	Mean Change From Baseline to Final Visit in Diastolic Blood Pressure (DBP).
NCT00867490 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Pressure During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Rate During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Rate During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
NCT01025843 (4) [back to overview]	Area Under the Plasma Concentration Versus Time Curve (AUC 0-infinity) of MK-5478 and Candesartan
NCT01025843 (4) [back to overview]	Maximum Plasma Concentration (Cmax) of MK-5478 and Candesartan
NCT01025843 (4) [back to overview]	Number of Participants Who Discontinued Treatment Due to an AE
NCT01025843 (4) [back to overview]	Number of Participants With One or More Adverse Events (AEs)
NCT01052272 (7) [back to overview]	Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA)
NCT01052272 (7) [back to overview]	Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA)
NCT01052272 (7) [back to overview]	Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV)
NCT01052272 (7) [back to overview]	Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness)
NCT01052272 (7) [back to overview]	LV End Systolic Maximum Shortening (LVES Max Shortening)
NCT01052272 (7) [back to overview]	Peak Early Filling Rate Normalized to EDV
NCT01052272 (7) [back to overview]	Left Ventricular Ejection Fraction (LVEF)
NCT01678794 (2) [back to overview]	Change in Glomerular Filtration Rate
NCT01678794 (2) [back to overview]	Change in Urinary Sodium Excretion
NCT01788358 (9) [back to overview]	Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 28
NCT01788358 (9) [back to overview]	Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 52/End of Study (EOS)
NCT01788358 (9) [back to overview]	Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 52/End of Study (EOS)
NCT01788358 (9) [back to overview]	Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28
NCT01788358 (9) [back to overview]	Change From Baseline In Mean Seated Systolic Blood Pressure (MSSBP) At Weeks 28 And 52
NCT01788358 (9) [back to overview]	Change From Baseline in Mean Seated Diastolic Blood Pressure (MSDBP) at Weeks 28 and 52
NCT01788358 (9) [back to overview]	Blood Pressure Response Rate at Weeks 28 and 52
NCT01788358 (9) [back to overview]	Blood Pressure Control Rate at Weeks 28 and 52
NCT01788358 (9) [back to overview]	Number of Subjects With Clinically Relevant Changes in Laboratory Parameters
NCT01794455 (2) [back to overview]	Montgomery-Asberg Depression Rating Scale
NCT01794455 (2) [back to overview]	Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)
NCT01938664 (3) [back to overview]	# of Participants Retained in Study
NCT01938664 (3) [back to overview]	# of Participants With Adverse Events
NCT01938664 (3) [back to overview]	# of Participants With Presence of Cocaine Metabolites Via Urinalysis
NCT01976572 (4) [back to overview]	Tmax
NCT01976572 (4) [back to overview]	T1/2
NCT01976572 (4) [back to overview]	Cmax of Candesartan
NCT01976572 (4) [back to overview]	AUC0-t of Candesartan
NCT01984164 (8) [back to overview]	"NINDS-initiated EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or EXAMINER Tool Box."
NCT01984164 (8) [back to overview]	Attention Measured Using Digit Span Backward
NCT01984164 (8) [back to overview]	Attention Measured Using Digit Span Forward
NCT01984164 (8) [back to overview]	Cerebral Perfusion
NCT01984164 (8) [back to overview]	Executive Function
NCT01984164 (8) [back to overview]	Language
NCT01984164 (8) [back to overview]	Memory
NCT01984164 (8) [back to overview]	White Matter Lesion Volume
NCT02016183 (4) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)
NCT02016183 (4) [back to overview]	Changes From Baseline in Diastolic Blood Pressure (DBP) at Each Time Point
NCT02016183 (4) [back to overview]	Changes From Baseline in Pulse Rate at Each Time Point
NCT02016183 (4) [back to overview]	Changes From Baseline in Systolic Blood Pressure (SBP) at Each Time Point
NCT02068495 (6) [back to overview]	Changes From Baseline in Diastolic Blood Pressure (DBP) at Final Assessment
NCT02068495 (6) [back to overview]	Percentage of Participants Who Meet Targeted Blood Pressure Level at Baseline and Final Assessment
NCT02068495 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Events
NCT02068495 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)
NCT02068495 (6) [back to overview]	Changes From Baseline in Systolic Blood Pressure (SBP) at Final Assessment
NCT02068495 (6) [back to overview]	Changes From Baseline in Pulse Rate at Final Assessment
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events Affected by Underlying Risk Factors of Obesity + Blood Glucose Abnormalities, Obesity + Lipid Abnormalities, or Blood Glucose Abnormalities + Lipid Abnormalities
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events
NCT02166697 (6) [back to overview]	Number of Participants Reporting One or More Serious Adverse Drug Reactions (SADR)
NCT02166697 (6) [back to overview]	Number of Participants Reporting One or More Adverse Drug Reactions (ADR)
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events Affected by Underlying Risk Factors of Obesity + Blood Glucose Abnormalities + Lipid Abnormalities
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events Affected by Underlying Risk Factors of Obesity, Blood Glucose Abnormalities, or Lipid Abnormalities
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Switched to Diuretic-containing ARB Combination Drug Therapy at Week 14
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Switched to Calcium Channel Blocker (CCB)-Containing ARB Combination Drug Therapy at Week 14
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Switched to ARB Combination Drug Therapy at Week 14
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Continued Candesartan Therapy at Week 14
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position
NCT02211638 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions
NCT02332824 (5) [back to overview]	Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12)
NCT02332824 (5) [back to overview]	Urine Albumin/Creatinine Ratio (UACR) at Each Assessment Point
NCT02332824 (5) [back to overview]	Remission Rate From Early-Stage Nephropathy (Stage 2) to Pre-Nephropathy Stage (Stage 1) at the End of Treatment (Week 12)
NCT02332824 (5) [back to overview]	Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12)
NCT02332824 (5) [back to overview]	Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
NCT02646982 (22) [back to overview]	Number of Participants With Elevated Serum Creatinine
NCT02646982 (22) [back to overview]	Number of Participants With Hyperkalemia
NCT02646982 (22) [back to overview]	Number of Participants With Hypotensive Episodes and Symptoms
NCT02646982 (22) [back to overview]	Number of Participants With Symptoms of Hypotension
NCT02646982 (22) [back to overview]	Vasoreactivity
NCT02646982 (22) [back to overview]	Augmentation Index (AI)
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Amyloid Aβ40 Levels
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Amyloid Aβ42/Aβ40 Levels
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) of Tau Phosphorylated at Threonine 181 (p-tau181) Levels
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Total Tau Levels
NCT02646982 (22) [back to overview]	Clinical Dementia Rating (CDR) Score
NCT02646982 (22) [back to overview]	Pulse Wave Velocity (PWV)
NCT02646982 (22) [back to overview]	Number of Participants With a Hypotensive Episode
NCT02646982 (22) [back to overview]	Hopkins Verbal Learning Test (HVLT) Delayed Recall Score
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Amyloid Aβ42 Levels
NCT02646982 (22) [back to overview]	Hippocampal Volume
NCT02646982 (22) [back to overview]	Global Standardized Uptake Value Ratio (SUVR) of [18F]T807
NCT02646982 (22) [back to overview]	EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) Toolbox Composite Score
NCT02646982 (22) [back to overview]	Global Standardized Uptake Value Ratio (SUVR) of (11)C-Pittsburgh Compound B ((11)C-PiB)
NCT02646982 (22) [back to overview]	Trail Making Test (TMT) Part B - A
NCT02646982 (22) [back to overview]	Number of Participants Discontinuing Study Medication
NCT02646982 (22) [back to overview]	Trail Making Test (TMT) Part B
NCT03640312 (17) [back to overview]	Percentage of Participants With Potentially Related Adverse Events
NCT03640312 (17) [back to overview]	Percentage of Participants With Serious Adverse Events (SAEs)
NCT03640312 (17) [back to overview]	Proportion of Patients With Adverse Event Free Hypertension Control
NCT03640312 (17) [back to overview]	Rate of Adverse Events of Special Interest
NCT03640312 (17) [back to overview]	Health-related Quality of Life
NCT03640312 (17) [back to overview]	Proportion of Patients With Hypertension Control
NCT03640312 (17) [back to overview]	Mean Diastolic Blood Pressure
NCT03640312 (17) [back to overview]	Mean Change in Blood Urea Nitrogen
NCT03640312 (17) [back to overview]	Change in Mean Systolic Blood Pressure
NCT03640312 (17) [back to overview]	Mean Change in Serum Creatinine
NCT03640312 (17) [back to overview]	Mean Change in Serum Potassium
NCT03640312 (17) [back to overview]	Mean Change in Serum Sodium
NCT03640312 (17) [back to overview]	Number of Patients Requiring Step up Treatment
NCT03640312 (17) [back to overview]	Medication Adherence
NCT03640312 (17) [back to overview]	Change in Mean Diastolic Blood Pressure
NCT03640312 (17) [back to overview]	Change in Mean Systolic Blood Pressure
NCT03640312 (17) [back to overview]	Mean Systolic Blood Pressure

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Intervention	participants (Number)
Glycemia Trial: Intensive Control	503
Glycemia Trial: Standard Control	543

Intervention	mm Hg (Least Squares Mean)
Placebo	-3.3
Candesartan 32 mg	-9.3
HCT 25 mg	-7.7
Candesartan/HCT 32/25 mg	-13.9

Intervention	mm Hg (Least Squares Mean)
Placebo	-3.7
Candesartan 32 mg	-13.1
HCT 25 mg	-11.6
Candesartan/HCT 32/25 mg	-21.4

Intervention	mg/g (Mean)
Candesartan 8 mg	794.0
Candesartan 16mg	639.9
Candesartan 32mg	819.0

Intervention	mmHg (Mean)
	Systolic	Diastolic
Candesartan 16mg	-13.30	-8.00
Candesartan 32mg	-16.10	-13.00
Candesartan 8 mg	-11.70	-8.90

Intervention	mg/dL (Mean)
Candesartan 8 mg	0.01
Candesartan 16mg	-0.17
Candesartan 32mg	-0.01

Intervention	pg/mL (Mean)
	Pre CPB	Post surgery	Postoperative day 1	Postoperative day 2
Candesartan (ARB)	6.44	144.76	218.16	243.72
Placebo	6.29	116.04	224.96	166.96
Ramipril (ACEI)	9.33	167.51	172.65	144.67

Intervention	ng/mL (Mean)
	Pre CPB	60min of CPB	Post surgery	Postoperative day 1	Postoperative day 2
Candesartan (ARB)	18.28	24.19	49.10	21.70	13.4
Placebo	15.14	20.43	39.69	31.83	21.59
Ramipril (ACEI)	16.25	19.41	41.62	26.27	17.33

Intervention	percentage of patients (Number)
	Dobutamine	Mlrinone	Norepinephrine	Epinephrine
Candesartan (ARB)	27.3	22.7	95.5	13.6
Placebo	35.7	25.0	85.7	7.1
Ramipril (ACEI)	29.2	25.0	79.2	4.3

Intervention	percentage of patients (Number)
	Packed red blood cells	Plasma	Platelets	Cryoprecipitate
Candesartan (ARB)	2.7	31.8	22.7	4.5
Placebo	67.9	60.7	46.4	7.1
Ramipril (ACEI)	62.5	29.2	29.2	4.2

Intervention	mmHg (Least Squares Mean)
Candesartan Cilexetil/Hydroclorozide Combination Therapy	-17.0
Candesartan Cilexetil Monotherapy	-14.1

Intervention	Percent change (Median)
Atacand .05 mg	0.0
Atacand .20 mg	-29.2
Atacand .40 mg	0.0

Intervention	mm Hg (Mean)
Atacand .05 mg	-5.2
Atacand .20 mg	-7.9
Atacand .40 mg	-11.1

Intervention	mm Hg (Mean)
Atacand .05 mg	-6.0
Atacand .20 mg	-8.9
Atacand .40 mg	-12.0

Intervention	Percent change (Median)
Atacand .05 mg	-11.1
Atacand .20 mg	-40.6
Atacand .40 mg	-50.0

Intervention	Percentage of patients (Number)
	msSBP response	msDBP response
Phase 2 - Aliskiren+HCTZ	37.4	34.1

Intervention	Percentage of patients (Number)
	msSBP response	msDBP response
Phase III - Aliskiren+HCTZ+Amlodipine	54.1	47.5

Intervention	Percentage of patients (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Phase 2 - Aliskiren+HCTZ	37.4	33.3

Intervention	umol.hr/L (Mean)
MK-5478 1 mg	0.236
MK-5478 2 mg	0.494
MK-5478 5 mg	1.87
MK-5478 8 mg	1.80
MK-5478 12 mg	1.36
MK-5478 18 mg	2.23
MK-5478 24 mg	3.15
MK-5478 38 mg	4.50
MK-5478 2 mg - Fed	0.504
Candesartan 32 mg	5.89
Candesartan 32 mg - Fed	4.46

Intervention	µmol/L (Mean)
MK-5478 1 mg	0.0291
MK-5478 2 mg	0.0573
MK-5478 5 mg	0.254
MK-5478 8 mg	0.227
MK-5478 12 mg	0.120
MK-5478 18 mg	0.245
MK-5478 24 mg	0.321
MK-5478 38 mg	0.532
MK-5478 2 mg - Fed	0.0553
Candesartan 32 mg	0.476
Candesartan 32 mg - Fed	0.451

Intervention	ml/m^2 (Mean)
	Month 0 (n=17,17,18,18)	Month 6(n=14,11,11,12)	Month 9(n=1,2,0,0)	Month12(n=12,11,11,11)	Month 15(n=3,2,1,1)	Month 18(n=10,12,8,8)	Month 21(n=3,0,0,1)	Month 24 (n=11,9,8,10)	Month 27 (n=1,1,0,1)
Candesartan Cilexetil	78.06	78.60	93.57	85.44	90.20	82.74	NA	84.28	76.65
Candesartan Cilexetil and Allopurinol	79.03	78.01	NA	79.75	63.1	84.95	75.27	79.72	75.05
Ramipril	73.03	74.10	73.23	75.34	81.19	75.28	71.99	70.46	48.68
Ramipril and Allopurinol	78.52	86.13	NA	83.95	108.25	67.96	NA	71.63	NA

Intervention	percent of length at end of filling (Mean)
	Month 0 (n=17,17,17,18)	Month 6(n=14,11,10,12)	Month 9(n=1,2,0,0)	Month 12(n=11,11,10,10)	Month 15(n=3,2,1,1)	Month 18(n=10,12,7,8)	Month 21(n=3,0,0,1)	Month 24 (n=11,9,8,10)	Month 27 (n=1,1,0,1)
Candesartan Cilexetil	16.68	17.50	19.08	17.13	16.28	17.55	NA	16.62	20.38
Candesartan Cilexetil and Allopurinol	16.00	18.50	NA	18.51	16.36	17.52	17.89	17.85	16.59
Ramipril	15.81	16.88	18.43	14.57	17.06	17.26	16.68	15.67	13.70
Ramipril and Allopurinol	15.84	18.72	NA	17.96	14.22	17.46	NA	17.52	NA

Intervention	Subjects (Number)
	Oedema (mild)	Oedema (moderate)	Oedema (severe)	Headache (mild)	Headache (moderate)	Flushing (mild)	Symptomatic hypotension (mild)
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	124	54	7	31	15	3	4

Intervention	Subjects (Number)
	Oedema (mild)	Oedema (moderate)	Oedema(severe)	Headache (mild)	Headache (moderate)	Flushing (mild)	Symptomatic hypotension (mild)
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	131	56	7	31	17	3	4

Intervention	Subjects (Number)
	All TEAEs	Drug-related TEAEs
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	404	238

candesartan

Description

Cross-References

Synonyms (131)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (2)

Pathways (1)

Protein Targets (39)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (398)

Molecular Functions (131)

Ceullar Components (64)

Bioassays (208)

Research

Studies (1,883)

Market Indicators

Research Demand Index: 122.63

Study Types

Clinical Trials (161)

Trial Overview

Trial Outcomes

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

Death From Any Cause in the Glycemia Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Stroke in the Blood Pressure Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28

Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)

Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP)

Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28

Number of Participants With at Least a 3 Step Improvement or a Persistent 2-step Improvement in the ETDRS Severity Scale.

Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).

Rate of Change in Urinary Albumin Excretion Rate (UAER).

Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale

Rate of Change in Urinary Albumin Excretion Rate (UAER).

Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale

Number of Participants With a Regression of Diabetic Retinopathy.

Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).

Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.

Rate of Change in Urinary Albumin Excretion Rate (UAER).

Change of Diastolic Blood Pressure (DBP)

Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine

Change of Systolic Blood Pressure (SBP)

LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index

Percent Change of B Type Natriuretic Peptides (BNP) Level

Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only

Number of CV Deaths

Changes in Health-related Quality of Life

Discontinuations

Total Number of Titration Steps in Prescribed Heart Failure Treatment

Changes in NT-proBNP Values Over Time in All Patients

Changes in Heart Failure Symptoms

Number of Days in Hospital for CV Reason

Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)

Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).

The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study

Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks)

The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks

Treatment-emergent Adverse Events

Change of Systolic and Diastolic Blood Pressure From Baseline

Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation

Inflammatory Marker (Hs-C-peptide Reactive Protein)

Blood Pressure Outcome: Systolic BP

Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall

Cognitive Assessment: Forward Digit Span Test

Cognitive Assessment: Trail Making Test Part B

Intervention	millimeter of mercury (mmHg) (Mean)
	Baseline	Change at Week 28	Change at Week 52
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	170.7	-30.4	-30.1

Intervention	percentage of subjects (Number)
	Week 28	Week 52
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	86.6	86.2

Intervention	participants (Number)
Candesartan w Cognitive Behavior Therapy	5
Placebo w Cognitive Behavior Therapy	0

Intervention	mmHg (Mean)
	Change in DBP at Month 1	Change in DBP at Month 2	Change in DBP at Month 3	Change in DBP at Month 4	Change in DBP at Month 5	Change in DBP at Month 6	Change in DBP at Month 7	Change in DBP at Month 8	Change in DBP at Month 9	Change in DBP at Month 10	Change in DBP at Month 11	Change in DBP at Month 12	Change in DBP at Final
Candesartan Cilexetil/Hydrochlorothiazide	-6.5	-7.3	-7.6	-7.8	-7.8	-8.0	-8.1	-8.2	-8.5	-8.7	-8.5	-9.1	-8.5

Intervention	Beats per minutes (Mean)
	Change in Pulse Rate at Month 1	Change in Pulse Rate at Month 2	Change in Pulse Rate at Month 3	Change in Pulse Rate at Month 4	Change in Pulse Rate at Month 5	Change in Pulse Rate at Month 6	Change in Pulse Rate at Month 7	Change in Pulse Rate at Month 8	Change in Pulse Rate at Month 9	Change in Pulse Rate at Month 10	Change in Pulse Rate at Month 11	Change in Pulse Rate at Month 12	Change in Pulse Rate at Final assessment
Candesartan Cilexetil/Hydrochlorothiazide	-1.3	-1.1	-1.3	-1.5	-1.3	-1.5	-1.1	-1.5	-1.6	-1.7	-1.5	-1.8	-1.6

Intervention	mmHg (Mean)
	Change in SBP at Month 1	Change in SBP at Month 2	Change in SBP at Month 3	Change in SBP at Month 4	Change in SBP at Month 5	Change in SBP at Month 6	Change in SBP at Month 7	Change in SBP at Month 8	Change in SBP at Month 9	Change in SBP at Month 10	Change in SBP at Month 11	Change in SBP at Month 12	Change in SBP at Final
Candesartan Cilexetil/Hydrochlorothiazide	-13.3	-14.8	-15.4	-15.7	-15.6	-16.1	-15.8	-15.8	-16.4	-16.6	-17.0	-18.1	-17.5

Intervention	Percentage of Participants (Number)
	Baseline	Final Assessment
Candesartan Cilexetil/Amlodipine	28.5	66.9

Intervention	Number of events/1,000 person-years (Number)
	Sudden Death	Cerebral Hemorrhage	Cerebral Infarction	Subarachnoid Hemorrhage	Acute Myocardial Infarction	Hospitalization for heart Failure	Intervention/Hospitalization for Angina Pectoris	Atrial Fibrillation	Transition to Dialysis	Renal Transplant	Dissecting Aortic Aneurysm	Diabetic Retinopathy	New-Onset Diabetes	Primary MACE	Primary MACE 2	Renal Events
Candesartan Cilexetil	0.20	0.53	2.19	0.13	1.06	0.33	1.33	1.46	0.07	0.00	0.07	0.07	4.51	4.11	5.77	0.07

Intervention	mmHg (Mean)
	Month 3, SBP	Last Dose of Candesartan, SBP	Last dose of ARB Combination Drug, SBP	Month 3, DBP	Last Dose of Candesartan, DBP	Last dose of ARB Combination Drug, DBP
Candesartan Cilexetil 4 mg to 8 mg	-21.7	-12.3	-26.4	-11.8	-6.4	-14.4

Intervention	log (mg/gCr) (Least Squares Mean)
Placebo	0.152
TAK-272 5 mg	-0.173
TAK-272 20 mg	-0.317
TAK-272 40 mg	-0.478
TAK-272 80 mg	-0.497
Candesartan Cilexetil 8 mg	-0.377